Drug, bio-affecting and body treating compositions inventions 09/07

20070224128 - Drug adherence monitoring system: The present invention provides novel methods for monitoring subject adherence in taking prescribed drugs by detecting markers in exhaled breath after a subject takes the prescribed drug. In particular, the present invention provides novel methods for making additives that are combined with the drug(s). Upon biological breakdown of the drug/additive... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070224134 - Oral zinc compositions: The present invention relates to an oral composition comprising, in an orally acceptable carrier, from about 0.1% to about 5% zinc oxide; and from about 0.1% to about 5% of a source of carbonate ions selected from alkali metal and ammonium carbonates and bicarbonates. The molar ratio of carbonate ion... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070224131 - Pet chew article: Pet chew articles comprising a consumable body having a shape defined by an exterior surface and comprising a main portion and at least one protrusion extending therefrom with the proviso that the shape of the body is such that no point in the interior of the body is more than... Agent: 3m Innovative Properties Company

20070224138 - Cosmetic composition comprising gingko biloba and sunscreen agents: A cosmetic composition is provided comprising a Gingko biloba extract, an alkyl β,β-diphenylacrylate and/or α-cyano β,β-diphenylacrylate derivative, and a dibenzoyl methane derivative. A cosmetic use of that composition is also provided for preventing sun damage and photo ageing.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070224139 - Cosmetic compositions: A topical composition having (i) an isolated polypeptide having the sequence of SEQ ID NO: 1 or a functional equivalent thereof, and (ii) a cosmetically acceptable carrier; and use thereof.... Agent: Fish & Richardson PC

20070224140 - Cosmetic or dermatologic compositions containing microspheres: The invention relates to cosmetic or dermatologic compositions comprising a microsphere and a film forming component.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224143 - Cosmetic and pharmaceutical foam carrier: The invention provides a quick-break, alcohol-free, cosmetic and pharmaceutical foam carrier comprising about 20%-60% hydrophobic volatile solvent, about 20%-60% water, about 3%-20% of polyol, and about 0.1%-7.5% of a surface active agent.... Agent: Bachman & Lapointe, P.C.

20070224149 - Foaming composition: A foaming composition is provided, which includes water, pulp, alginic ester, and a surfactant. A preferable example of the alginic ester is propylene glycol alginate. The alginic ester may be mixed therein at a mixing amount ranging from 5 parts by weight to 15 parts by weight based on 100... Agent: Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070224156 - Shampoo formulation for animals: A shampoo for animals is disclosed. The shampoo formulation comprises Vitamin A and Vitamin E. In certain embodiments, the shampoo formulation further comprises one or more fruit extracts. In certain embodiments, those one or more fruit extracts are selected from the group consisting of Carica Papaya Fruit Extract, Psidiuim Guajava... Agent: Dale F. Regelman

20070224160 - Nonleachable composition and method to use: This invention relates to a nonleachable waterborne wood preservative composition that combines one or more resin acids, mostly or fully in the carboxylate anion form, with one or more organic biocides to enhance the efficacy of relatively high-cost organic biocides. Resin acids are cost effective and environmentally safe, and therefore... Agent: Butler, Snow, O'mara, Stevens & Cannada PLLC

20070224173 - Nonexpansion protocol for autologous cell-based therapies: The present application describes various applications of the non-expansion protocol for the preparation of an injectable autologous cell mixture of the present invention that can be used to prevent symptoms in a number of indications. Cells are isolated from surgically derived tissue and are at least partially disaggregated from each... Agent: Ams Research Corporation

20070224116 - Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents: The invention relates generally to a medical device, such as an intravascular stent, for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. More particularly, the invention pertains to a medical device having a metal oxide or metal material... Agent: Jones Day

20070224115 - Polymeric chelators for radionuclide delivery systems: A radionuclide delivery system that is based upon amorphous, water-soluble polymeric chelators. Each water-soluble polymeric chelator is capable of delivering hundreds of radionuclide atoms to the target. The chemical and physical characteristics of the globular polymer increase the effective decay-particle yield at the target cells and reduce ancillary toxicity due... Agent: Los Alamos National Security, LLC

20070224117 - Technetium-99m-labeled organic germanium nanocolloids, method of preparing the same and use thereof: Disclosed relates to organic germanium nanocolloids, to which technetium-99m (99mTc), a radionuclide, is labeled, method of the same, and a spleen-imaging agent including the same. According to the invention, 99mTc-labeled organic germanium nanocolloids having high labeling efficiency and stability can be provided. Moreover, since the 99mTc-labeled organic germanium nanocolloids of... Agent: Lucas & Mercanti, LLP

20070224118 - Methods for soluble zalpha11 cytokine receptors: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding... Agent: Zymogenetics, Inc. Intellectual Property Department

20070224119 - Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer: The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin... Agent: Cyr & Associates, P.A.

20070224120 - Novel 150-labeled monosaccharide and producing method thereof: This invention relates to novel 15O-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224121 - Connective tissue growth factor-4: The present invention relates to a novel human protein called Connective Tissue Growth Factor-4, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070224124 - Novel sh2containing inositol 5'-phosphatase isoform that partners with the grb2 adapter protein: SH2 containing inositol 5′-phosphate (SHIP) modulates the activation of immune cells after recruitment to the membrane by Shc and the cytoplasmic tails of receptors. A novel SHIP isoform of approximately 104 kd expressed in primitive stem cell populations (s-SHIP) is described. It was found that s-SHIP is expressed in totipotent... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070224122 - Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines: The invention provides polypeptides encoded by open reading frames present in the genome of Mycobacterium tuberculosis but absent from the genome of BCG and diagnostic and prophylactic methodologies using these polypeptides.... Agent: Fish & Richardson P.C.

20070224123 - Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines: The invention provides polypeptides encoded by open reading frames present in the genome of Mycobacterium tuberculosis but absent from the genome of BCG and diagnostic and prophylactic methodologies using these polypeptides.... Agent: Fish & Richardson P.C.

20070224125 - Cc-chemokine binding tick proteins: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070224127 - Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure: The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20070224126 - Index and method of use of adapted food compositions for dysphagic persons: The present invention provides a method in which a quantitative and descriptive approach is used to adapt the food texture in the clinical management of dysphagia. There is provided a new index, ST index, and method of use for determining and modulating the physical characteristics of foods in a manner... Agent: Ogilvy Renault LLP

20070224129 - Anti-misuse microparticulate oral pharmaceutical form: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic... Agent: Patton Boggs LLP

20070224130 - Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators: when X represents C—H or C—CH3, Y represents N when X represents N, Y represents C—H and physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070224133 - High-cleaning silica materials made via product morphology control under high shear conditions: Unique abrasive materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial, particularly simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels. Such a result thus accords the user a dentifrice that effectively cleans tooth surfaces without detrimentally... Agent: William S. Parks, Esq. J. M. Huber Corporation

20070224132 - High-cleaning, low abrasion, high brightness silica materials for dentrifices: Unique abrasive materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial, particularly simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels. Such a result thus accords the user a dentifrice that effectively cleans tooth surfaces without detrimentally... Agent: William S. Parks, Esq. J.m. Huber Corporation

20070224137 - Methods of increasing lymphatic function: This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.... Agent: Fish & Richardson PC

20070224135 - Stable aqueous suspension concentrate for delivery of uv-labile water-insoluble biocides: A stable, aqueous suspension concentrate which includes a solid polymeric dispersant comprising one or more anionic polymeric dispersing agents, optionally a co-dispersant which preferably is a homopolymer and/or a copolymer of a heterocyclic vinyl lactam, preferably in a wt. ratio of 0.1:1 to 1:0.1, a UV-labile, water-insoluble biocide active, and... Agent: International Specialty Products

20070224136 - Topical composition and method for improving skin characteristics: A topical composition and a method for improving skin characteristics are described. The topical composition comprises a mixture physical scatterers having a neat particle size from about 5 to less than about 100 nm and greater than about 300 nm to about 2 microns. The topical composition of the present... Agent: Unilever Intellectual Property Group

20070224141 - Kit containing two compositions: The present invention relates to a kit containing a first and a second cosmetic composition, the first composition containing at least one silicone elastomer and concave particles of a siliconized material, notably in the form of portions of hollow spheres, the second composition containing a physiologically acceptable medium. This kit... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224142 - Hydrogenated castor oil based compositions as a replacement for petrolatum: An aqueous deodorant composition comprising (a) from about 0.1% to about 89.9% by weight of a hydrogenated castor oil based composition comprising a first oil, said first oil comprising hydrogenated castor oil, and a second oil to soften the hydrogenated castor oil; (b) from about 0.1% to about 30% by... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070224144 - process for the preparation of cosmetic products with powders having different features: There is described a process for the preparation of a cosmetic product with powders (1, 20, 57) having different features, specifically being multicoloured, carried out by the steps of precipitating cosmetic powders, compressing, forming cavities (9, 26, 49), and exciding excesses. It is possible to obtain a cosmetic product (1,... Agent: Akerman Senterfitt

20070224146 - Method of stabilizing silica-containing anionic microparticles in hard water: A method of stabilizing silica-containing anionic microparticles upon mixing of the silica-containing anionic microparticles with hard water comprising adding one or more hardness-abating additives to the hard water prior to mixing of the hard water and the silica-containing anionic microparticles; or adding an effective stabilizing amount of one or more... Agent: Michael B. Martin Patent And Licensing Department

20070224147 - Uv-photoprotecting/sunscreen compositions comprising silane/siloxane derivatives of merocyanine sulfones: Topically applicable cosmetic compositions useful for the UV-A photoprotection of the skin and/or hair contain thus effective amounts of at least one silane, siloxane or polysiloxane merocyanine sulfone having at least one of the structural formulae (1), (2) and (3) below:... Agent: Buchanan, Ingersoll & Rooney PC

20070224148 - Beta-(1,3)-beta-(1,4)-glucan as carrier for chemical substances: Disclosed is the use of β-(1,3)-β-(1,4)-glucan (a) as carrier for carrying a chemical substance through the stratum corneum into deeper layers of the skin and/or (b) for improving the penetration abilities of the chemical substance through the stratum corneum into deeper layers of the skin.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070224150 - Growth factor for hair and skin treatment: The present invention relates to a method of treatment for slowing the progress of skin aging comprising contacting the skin with an amount effective to slow skin aging of a composition comprising one or more compounds selected from the group consisting of EGF, bFGF, IGF-1, KGF, TGF-β3, TRX, VEGF, TRX,... Agent: Sonnenschein Nath & Rosenthal LLP

20070224151 - Cosmetic composition comprising at least one specific block copolymer: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: at least one fatty phase, and at least one block copolymer of rod-coil type comprising at least one coil polymeric block structure with a variable conformation covalently bonded to at least one rod polymeric block structure... Agent: Oliff & Berridge, PLC

20070224152 - Hair cleansing composition: A hair cleansing composition containing the following components (A), (B) and (C): (A) 0.1 to 20 wt. % of an organic dicarboxylic acid which may have a hydroxy group, a hydroxycarboxylic acid, or a salt thereof; (B) 0.001 to 10 wt. % of an at least one antiphlogistics; (C) 0.5... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224145 - Thickened hair-treatment agent containing water glass: Described is a hair-treatment agent in the form of a thickened preparation on an aqueous basis and containing at least one polymeric gel former bearing acid groups, water glass in an amount sufficient for partly or completely neutralizing the acid groups of the polymeric gel former and at least one... Agent: Michael J. Striker

20070224155 - Cleansing compositions and methods of reducing skin irritation: Cleansing compositions are described that comprise at least one surfactant, at least one extract of a Lamiaceae family plant, and at least one extract of a Liliaceae family plant. The at least one extract of the Lamiaceae family plant and the at least one extract of the Liliaceae family plant... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070224153 - High-deposition compositions and uses thereof: Provided are compositions comprising actives associated with cationically-charged delivery systems, which compositions tend to exhibit relatively high-deposition of the actives onto the skin, nails, vagina and/or hair upon application thereto, and methods of use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070224154 - Methods of reducing skin irritation: Methods of reducing skin irritation induced by a surfactant are described that comprise contacting skin with a detergent comprising at least one surfactant and at least one botanical extract, wherein the at least one botanical extract at least partially counteracts irritation induced by the at least one surfactant.... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070224157 - Antibacterial deodorizer kit for refrigerator and purifying system using the same: An embodiment in the present invention, a cold air inlet port of a refrigerating chamber of a refrigerator is provided with an antibacterial deodorizer kit, which is formed by injection-molding deodorizing agent containing antibacterial capsules. The antibacterial capsules are formed by microcapsulizing the antibacterial substance. A cold air discharge port... Agent: Birch Stewart Kolasch & Birch

20070224158 - Method for the cosmetic treatment of wrinkled skin using a cosmetic composition containing a tightening agent and a dispersion of solid particles of a grafted acrylic polymer: The present invention relates to a cosmetic process for softening the wrinkles of wrinkled skin comprising a stage consisting in applying, to said wrinkled skin, a cosmetic composition, in particular an anti-wrinkle composition, comprising, in a physiologically acceptable medium suitable for topical application to the skin of the face: from... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224159 - Ophthalmic compositions containing a synergistic combination of three polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.... Agent: Alcon

20070224163 - Absorbable alpha- cyanoacrylate compositions: n is from 2 to 12; R3 and R4 are each an alkyl group or a hydrogen, and at least one of R3 or R4 is an alkyl group (e.g. linear or branched, or cyclic) having from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and... Agent: Philip S. Johnson Johnson & Johnson

20070224162 - Antimicrobial releasing polymers: The present disclosure is directed to polymers having hydroxyl containing bioactive agents incorporated into the backbone of the polymer or attached thereto by pendant linkages. Hydroxyl containing bioactive agents which may be attached to these polymers include antimicrobial agents such as triclosan. The polymers may be utilized to form medical... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070224161 - Compositions and methods for making and using acyclic n-halamine-based biocidal polymeric materials and articles: The present invention includes methods and compositions for providing rechargeable aliphatic N-halamine polymers, monomers, copolymers additives and coatings. The rechargeable aliphatic N-halamine includes an aliphatic N-halamine compound exchangeable associated with one or more halides.... Agent: Chalker Flores, LLP

20070224164 - Degradable nanogel for drug delivery: A nano-sized hydrogel is made of a water-soluble chain containing carboxylic acid moieties and polyethylene side chains. Such a nanogel is applicable as a cancer-drug delivery agent or an imagining agent, where either a cancer drug, such as cisplatin, or an imaging agent, such as Gd3+. The complexation of the... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center

20070224165 - Neuroprotective effects of gly-pro-glu following intravenous infusion: Gly-Pro-Glu (GPE) is rapidly metabolized in vivo. We found that GPE infusion elicits potent and consistent neuroprotection in all brain regions examined, and in certain embodiments, the effects were greater than those of a bolus injection followed by infusion (“loading dose/infusion”). GPE reduced apoptosis in the hippocampus and inhibited microglial... Agent: Borson Law Group, PC

20070224166 - Uses of mammalian cytokine; related reagents: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.... Agent: Dnax Research Inc. Legal Department

20070224167 - Novel hcv inhibitor combinations and methods: Novel hepatitis C virus (“HCV”) inhibitor combinations comprising an HCV protease inhibitor and HCV polymerase inhibitor, and optionally one or more biologically active agents, as well as uses of these combinations as HCV inhibitors and for treating hepatitis C and related disorders are disclosed.... Agent: Cheryl H Agris Phd

20070224168 - Isolated muscle satellite cells, use thereof in muscle tissue repair and method for isolating said muscle satellite cells: The present invention relates to the field of tissue engineering, and more particularly to isolated muscle satellite cells, their use for repairing damaged muscle tissues and a method for isolating said muscle satellite cells. Consequently, the present invention relates to isolated muscle satellite cells and a method for isolating muscle... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224170 - Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells: The present invention relates to a genic expression adenoviral hybrid vector characterized in that it contains at least the following elements, oriented in the direction 5′ to 3′: i. a first chain of adenoviral origin comprising a first inverted terminal repeat (ITR) sequence and a signal sequence for packaging of... Agent: Moore & Van Allen PLLC

20070224171 - Genetically engineered cells for therapeutic applications: An isolated mesenchymal stem cell, multipotent adult progenitor cell, or other stem cells is genetically modified to express at least one of CXCR4, SDF-1, or a variant thereof.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070224169 - Selectively switched gels for surgery, therapy and maintenance: A gel-like material is provided, the gel-like material having an on-demand state-change capability, whether the on-demand change is to an initial state, a final state or both, at least some of the gel present or delivered undergoing the change. Alternatively, the gel-like material may have a spatially and/or temporally selective... Agent: David W. Collins Intellectual Property Law

20070224177 - Cell populations which co-express cd49c and cd90: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070224176 - Delivery of dna or rna via gap junctions from host cells to target cells and a cell-based delivery system for antisense or sirna: A method of delivering an oligonucleotide or a plasmid expressing an oligonucleotide into a target cell comprises introducing an oligonucleotide into a donor cell, particularly a stem cell, and contacting the target cell with the donor cell under conditions permitting the donor cell to form a gap junction with the... Agent: Kenyon & Kenyon LLP

20070224178 - Multimeric constructs: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular... Agent: Genzyme Corporation Legal Department

20070224179 - Bacillus mycoides isolate that induces systemic resistance: A method of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to the foliage of said plant wherein said plant is capable of producing defense proteins.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070224174 - Natural killer cell compositions and method for production of the same: The subject matter of the present invention relates to a ligand of Axl receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer cell. In addition, it relates to a process for producing mature natural killer cell comprising treating hematopoietic stem cells with... Agent: Knobbe Martens Olson & Bear LLP

20070224175 - Salt and ph tunable resist patterns on polyelectrolyte multilayers: A method for selectively removing a resist material from the polycationic surface of a polyelectrolyte multilayer (PEM) film, without disturbing adhering interactions between the cationic film surface and bound biomaterials such as cells, proteins, and nucleic acids. The resist material is one that that inhibits or prevents the further deposition... Agent: Harness, Dickey & Pierce, P.L.C

20070224172 - Tissue repair with multipotent cells: The invention relates to the field of medical science, in particular to technology directed at repairing defects in living, preferably human, tissue. The present invention provides a method for inducing differentiation of multipotent cells to a desired cell type, as well as a method for repairing a tissue defect in... Agent: Morrison & Foerster LLP

20070224180 - Screening and treatment methods using igs5 enzymes of the metalloprotease family: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5... Agent: Crowell & Moring LLP Intellectual Property Group

20070224181 - Arp as an inducer of granulocytopoiesis, uses and methods thereof: The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070224182 - Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells: A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include... Agent: Victorio C. Rodriguez

20070224183 - Compositions and methods for treating collagen-mediated diseases: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved... Agent: Elmore Patent Law Group, PC

20070224184 - Method for treating cellulite: The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective... Agent: The Farrell Law Firm, P.C.

20070224186 - Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070224185 - Secreted and transmembrane polypeptides and nucleic acids encoding the same: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides... Agent: Genentech, Inc.

20070224187 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Ilya Zborovsky

20070224190 - Anti-amyloid immunogenic compositions, methods and uses: The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of Aβ42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Trx). Polypeptides bearing multiple copies of Aβ42 fragments, preferably with an interposed amino acid linker, were constructed and... Agent: Young & Thompson

20070224189 - Cd20 optimized fc variants and methods for their generation: The present invention relates to CD20 optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070224191 - Methods of treatment of ulcerative colitis and crohn's disease with anti-cd3 antibodies: The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of ulcerative colitis or Crohn's disease comprising administering to a subject a therapeutically effective amount of a pharmaceutical formulation comprising an antibody, wherein said antibody binds to CD3.... Agent: Townsend And Townsend And Crew LLP

20070224192 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070224188 - Variant fc regions: The present invention provides polypeptides, particularly therapeutic antibodies, comprising a novel, variant Fc region. Furthermore the invention provides variant Fc regions which confer an altered effector function or altered serum half life upon a polypeptide to which it is operable attached.... Agent: Eli Lilly & Company

20070224193 - Methods of increasing lean tissue mass using ob protein compositions: DNA sequences comprising nucleic acids encoding fusion proteins comprising an Fc portion of an antibody attached at the N-terminus of an OB protein moiety, vectors comprising such DNA sequences, host cells comprising such vectors or DNA sequences, and processes for preparing such fusion proteins, and pharmaceutical compositions comprising such fusion... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20070224194 - Methods for inhibiting angiogenesis and/or lymphangiogenesis: Proprotein convertase inhibitor has been found to block proteolytic processing and activation of VEGF-C and VEGF-D and inhibit angiogenesis and/or lymphangiogenesis. Method and composition are disclosed for inhibiting angiogenesis and/or lymphangiogenesis, and for treating conditions associated with excessive angiogenesis, such as tumors and/or retinopathies, as well as conditions associated with... Agent: Marshall, Gerstein & Borun LLP

20070224195 - Modified vaccinia ankara expressing p53 in cancer immunotherapy: Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an... Agent: Perkins Coie LLP

20070224196 - Immunogenicity-reduced anti-cr1 antibody and compositions and methods of treatment based thereon: The invention provides immunogenicity-reduced antibodies or antibody fragments that bind a human CR1 receptor. The immunogenicity-reduced anti-CR1 antibody of the invention comprises one or more non-human sequences modified to comprise one or more amino acid substitutions so that the immunogenicity-reduced antibody id non-immunogenic or less immunogenic to a human. The... Agent: Lahive & Cockfield, LLP

20070224197 - Three-dimensional structure of complement receptor type 2 and uses thereof: Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural... Agent: Sheridan Ross PC

20070224198 - Antithrombotic agents: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis in combination with plasminogen activators are disclosed.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070224200 - Gm3 synthase as a therapeutic target in microvascular complications of diabetes: The present invention relates to the use of an inhibitor of the expression or activity of the GM3 synthase gene for the treatment of microvascular complications of diabetes, and to a method of screening compounds useful in the treatment and/or prevention of these complications.... Agent: Millen, White, Zelano & Branigan, P.C.

20070224199 - Targeting of mkrn1 for identifying cancer treatment agents: Disclosed herein are novel methods for screening for compounds useful in treating telomerase positive cancers. In exemplary embodiments, screening methods are based on the implementation or manipulation of therapeutic agents that up-regulate activity or expression of MKRN polypeptides or polynucleotides encoding the same, respectively. The methods are useful in identifying... Agent: Beusse Wolter Sanks Mora & Maire

20070224203 - Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2: The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070224201 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070224202 - Use of antibodies for the vaccination against cancer: Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases.... Agent: Birch Stewart Kolasch & Birch

20070224204 - Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents: Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20070224205 - Compositions that include hemagglutinin, methods of making and methods of use thereof: Compositions comprise a flagellin component or a Toll-like Receptor agonist component that is at least a portion of a flagellin or a Toll-like Receptor agonist, wherein the flagellin component or Toll-like Receptor agonist component includes at least one cysteine residue and whereby the flagellin component or Toll-like Receptor agonist component... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070224206 - Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions: Whole organisms are inactivated by at least a factor of 106 using carbon dioxide at or near its supercritical pressure and temperature conditions.... Agent: Welsh & Flaxman LLC

20070224208 - Ras mutation and compositions and methods related thereto: Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.... Agent: Sheridan Ross PC

20070224207 - Reagents and methods for cancer treatment and prevention: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at... Agent: Medlen & Carroll, LLP

20070224209 - Therapeutic uses of glandular kallikrein: An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the... Agent: Merchant & Gould PC

20070224210 - Immunostimulatory nucleic acids: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.... Agent: Wolf Greenfield & Sacks, P.C.

20070224211 - Hiv-1 glycopeptides and derivatives; preparation and applications thereof: A method of making a synthetic glycopeptide, by addition of a synthetic oligosaccharide oxazoline to a GlcNAc-containing peptide precursor in the presence of an enzyme selected from among Endo-A and Endo-M. In a specific implementation, the method is utilized to synthesize a trivalent V3-domain glycopeptide including three V3-domain glycopeptides on... Agent: Intellectual Property / Technology Law

20070224212 - Stable peptide mimetic of hiv gp41 fusion intermediate: Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly... Agent: Merck And Co., Inc

20070224214 - Composition exerting physiological activity via biological immune mechanism: It is intended to provide a low-molecular weight component (or fraction) originating in Agaricus Blazei Muril which is excellent in digestion and absorption properties in vivo and exerts a physiological activity via the immune mechanism in vivo, and a food material or a drug material. Namely, a composition exerting a... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20070224213 - Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications: The present invention relates to a non-polar solvent soluble extract, polyphenol fractions therefrom and the compounds isolated from Elfvingia applanata, which shows a therapeutic activity for diabetes and diabetic complications, and a pharmaceutical composition for the treatment of diabetes and diabetic complications comprising the same.... Agent: Kirk Hahn

20070224215 - Brown seaweed extracts in capsules consisting of broad-spectrum freeze dried antioxidant concentrates, fucoidan, crystalloidals, mangosteen, hyaluronic acid, alpha lipoic acid, green tea extract, vitamin c, and black pepper extract with delivery systems f: Method of making a Fucoidan Brown seaweed capsule with one or more or more of the following ingredients: freeze dried white and concord grape polyphenol carotenoid concentrate, mangosteen, freeze dried blueberry polyphenol carotenoid concentrate, freeze dried brown seaweed brown seaweed fucoidan carotenoid concentrate, black pepper extract, xyonix crystalloidal matrix, DMAE,... Agent: Kevin Buckman

20070224216 - Methods and compositions related to antiviral therapy using algae and cyanobacteria: Disclosed are methods and compositions related to treating and preventing viral infection.... Agent: Needle & Rosenberg, P.C.

20070224217 - Virulence genes of m. marinum and m. tuberculosis: Methods for identifying, isolating and mutagenizing virulence genes of mycobacteria, e.g., M. marinum and M. tuberculosis, are described. Also described are isolated virulence genes and fragments of them, isolated gene products and fragments of them, avirulent bacteria in which one or more virulence genes are mutagenized, attenuated vaccines containing such... Agent: Millen, White, Zelano & Branigan, P.C.

20070224218 - Viral antigens: The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.... Agent: Glaxosmithkline

20070224220 - Intranasal or inhalational administration of virosomes: The present invention provides a composition of influenza virosomes comprising reconstituted envelopes of said virus, wherein the viral envelopes are entirely derived from influenza viral particles, wherein no lipid is added from an external source to the reconstituted virosomes, wherein the virosomes comprise the influenza antigens haemagglutinin and/or neuraminidase or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070224219 - Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.... Agent: Nixon & Vanderhye, PC

20070224221 - Botulinum toxin neurotoxic component for treating juvenile cerebral palsy: The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.... Agent: Allergan, Inc.

20070224222 - Neisserial vaccines: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070224223 - Methods for the in vitro culture of sporozoea sp. and uses thereof: The invention relates to a method of excysting and growing protozoal oocysts by in vitro tissue culture resulting in production of a continuous culture of merozoites. The invention also provides an economical and reliable supply of cultured Eimeria sp. for vaccine production, assays and research. Domesticated avians that have been... Agent: Lucas & Mercanti, LLP

20070224224 - Protozoan strains of reduced virulence and use thereof: The present invention relates to a protozoan strain of the family of the Trypanosomatidae the virulence of which is lower than that of the corresponding wild-type strain, characterized in that at least one copy of the SIR2 gene present in the genome of the strain is inactivated.... Agent: Young & Thompson

20070224225 - Immune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer: The composition for stimulating an immune response in a subject comprises methyl vinyl ether and maleic anhydride copolymer-based nanoparticles. Said nanoparticles may further contain an allergen or an antigen and/or an immunostimulating agent, which may be contained inside said nanoparticles and/or at least partially coating the surface of said nanoparticles,... Agent: Intellectual Property / Technology Law

20070224226 - Composition and method of use thereof: A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at... Agent: Harness, Dickey, & Pierce, P.l.c

20070224229 - Cosmetic composition comprising seabuckthorn: Cosmetic compositions are provided comprising a hydrophilic extract of Seabuckthorn and a hydrophilic vitamin component. The cosmetic use of that composition is also provided.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070224230 - Cosmetic composition based on zinc and copper sulphates and sucralphate: The invention relates to a cosmetic composition comprising an association of sucralphate and a mixture of zinc and copper sulphates in an excipient suitable for topical application to the skin. More specifically, said composition is intended for the regenerating, healing and/or anti-inflammatory treatment of the skin.... Agent: The Firm Of Hueschen And Sage

20070224228 - Soap bars having ultraviolet radiation protection: The present invention is drawn to a soap bar that after the washing process leaves a residual deposit on a substrate that provides protection from ultraviolet radiation comprising (a) soap, a fatty carboxylic acid that has been saponified with either sodium hydroxide, potassium hydroxide, ammonium hydroxide, or mixtures thereof; (b)... Agent: Louis C. Paul Louis C. Paul & Associates

20070224227 - Stick type cosmetic and production process for the same: In order to provide a stick type cosmetic in which applying feeling can freely be set either hard or soft according to a size and a distribution of mesopores or the kind of a material while maintaining a satisfactory color developing property and satisfactory drawn line intensity and which is... Agent: Buchanan, Ingersoll & Rooney PC

20070224231 - Anti acne skincare composition and skincare article: There is disclosed a cleansing and moisturising composition for topical application to the skin. The composition comprises salicylic acid as active ingredient, and has the form of an emulsion comprising 70-95% by weight of an aqueous phase and 5-30% by weight of an oil phase, the salicylic acid being dissolved... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070224232 - Composition and method to repel insects: The present invention comprises methods and compositions for repelling insects. The compositions and methods comprise combinations of essential oils or materials that can be extracted from essential oils to repel insects. The essential oil blends can be combined with various gellants and used in devices that actively disperse the volatiles... Agent: Troutman Sanders LLP

20070224233 - Controlled-release agricultural chemical formulation: An object of the present invention is to provide an agricultural chemical formulation which is able to control release of an agricultural chemical active ingredient. This agricultural chemical formulation includes a composition, containing an agricultural chemical active ingredient, styrene-maleic anhydride copolymer or mixture of styrene-maleic anhydride copolymer and polymer having... Agent: Darby & Darby P.C.

20070224237 - Barbed sutures having a therapeutic agent thereon: A barbed suture having a therapeutic agent.... Agent: Philip S. Johnson Johnson & Johnson

20070224238 - Implants for replacing hyaline cartilage, with hydrogel reinforced by three-dimensional fiber arrays: Implants with hydrogel layers reinforced by three-dimensional fiber arrays can replace hyaline cartilage. Such implants should replace an entire cartilage segment, rather than creating a crevice around a plug, so these implants must be thin and flat, they must cover large areas, the tips of any tufts or stitches must... Agent: Patrick D. Kelly

20070224243 - Medical devices and methods of making medical devices: A medical device material impregnated with a combination of antimicrobial agents, the combination of antimicrobial agents comprising a first antimicrobial agent, the first antimicrobial agent being triclosan and at least a second antimicrobial agent, wherein the combination of antimicrobial agents provides the device material with antimicrobial activity and inhibition of... Agent: Baker Botts L.L.P.

20070224234 - Medical devices having biodegradable polymeric regions: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more biodegradable polymeric regions. These biodegradable polymeric regions, in turn, contain one or more polymers, at least one of which is a biodegradable copolymer that includes: (a) one or more amorphous... Agent: Mayer & Williams PC

20070224235 - Medical devices having nanoporous coatings for controlled therapeutic agent delivery: According to an aspect of the present invention, implantable or insertable medical devices are provided which contain (a) one or more depressions that contain at least one therapeutic agent, and (b) a nanoporous coating, disposed over the therapeutic-agent-containing depressions, which regulate transport of species between the therapeutic-agent-containing depressions and the... Agent: Mayer & Williams PC

20070224236 - Medical devices having polymer brushes: According to an aspect of the present invention, internal medical devices are provided, which contain at least one surface region that comprises a polymer brush. The polymer brush, in turn, contains one or more types of hydrophobic polymer chains and one or more types of hydrophilic polymer chains.... Agent: Mayer & Williams PC

20070224239 - Method of making a coated medical device: The present invention relates to a method of making a coated medical device with a porous coating. The method includes coating at least a portion of the surface of a medical device with a coating composition comprising a polymer, solvent, and a gas, and then removing an amount of gas... Agent: Jones Day

20070224240 - Methods of administering rapamycin analogs with anti-inflammatories using medical devices: e

20070224241 - Temperature- and ph-responsive polymer compositions: Temperature- and pH-responsive copolymer compositions, and drug delivery devices, conjugates, nanoparticles, and micelles that include the compositions.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070224242 - Tetrahedral amorphous carbon coated medical devices: A medical device, such as an orthopedic or prosthetic joint, has a protective coating bonded to the substrate material of the device. Suitable substrate materials may include pure metals and metal alloys, ceramics, polymers and composites of the above. The protective coating includes a thin layer of tetrahedral bonded Carbon... Agent: Dickinson Wright PLLC

20070224244 - Corrosion resistant coatings for biodegradable metallic implants: According to an aspect of the invention, implantable medical devices are provided which contain at least one biodegradable metallic region and a polymeric corrosion resistant coating over the biodegradable metallic region. The polymeric corrosion resistant coating slows the rate of corrosion of the biodegradable metallic region upon implantation into a... Agent: Mayer & Williams PC

20070224245 - Poly (diol co-citrate) hydroxyapatite composite for tissue engineering and orthopaedic fixation devices: The present invention is directed to a novel poly (diol citrates)-based bioceramic composite materials created using completely biodegradable and a bioceramic material polymers that may be used in implantable devices. More specifically, the specification describes methods and compositions for making and using bioceramic composites comprised of citric acid copolymers and... Agent: Marshall, Gerstein & Borun LLP

20070224247 - Biodegradable hydrophobic polysaccharide-based drug delivery implants: Medical implants formed of hydrophobic derivatives of natural biodegradable polysaccharides and that include bioactive agent are described. The implants demonstrate desirable bioactive agent release profiles and can be prepared to have high drug loading. The implants can be used to treat medical conditions, such as those requiring prolonged administration of... Agent: Kagan Binder, PLLC

20070224246 - Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a... Agent: Stout, Uxa, Buyan & Mullins LLP

20070224248 - Method and compositions for treating acne: A method and composition for treating acne. The present invention involves treatment of this medical condition with an oral administration of a mixture comprised of inorganic nickel compound(s) such as nickel sulfate, inorganic bromide compound(s) such as potassium bromide, inorganic zinc compound(s), and sulphur.... Agent: Miles Smith

20070224249 - Substantially dry disposable device for creating ready-to-use solutions for cleaning and inhibiting the formation of biofilms on surfaces: A substantially dry disposable device for creating ready-to-use solutions effective in cleaning and inhibiting the growth and formation of biofilms on surfaces and methods of manufacturing the same are disclosed. The device is impregnated with a concentrated formulation comprising a fermentation supernatant directly as obtained from the fermentation of Saccharomyces... Agent: Evelyn M. Sommer

20070224250 - Mold-resistant construction materials: Mold-resistant construction materials distinguished by the presence therein of an azole alone or in combination with a sporulation inhibitor and/or with a substance which is antiadhesive with respect to microorganisms.... Agent: Henkel Corporation

20070224251 - Hemostatic material: The present invention provides a hemostatic material which is excellent in hemostatic property, biodegradability and bioabsorbability, uniformity and stability of the quality, as well as reduces a risk of contamination with a pathogenic organism derived from an animal. The hemostatic material comprises a thrombin and a synthetic polypeptide capable of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070224252 - Microprojections with capillary control features and method: The present invention provides methods and devices for reducing the coating variability of a transdermal microprojection delivery device. The device includes one or more stratum corneum-piercing microprojections, wherein each microprojection has a capillary control feature that restricts migration of a coating formulation.... Agent: Philip S. Johnson Johnson & Johnson

20070224254 - Transdermal delivery patch: A transdermal delivery patch includes: a matrix; a volatile component; and a plurality of microcapsules dispersed in the matrix. Each of the microcapsules has an enclosing wall enclosing the volatile component therein. A method for preparing the transdermal delivery patch includes: mixing a first gel, a second gel with a... Agent: Merchant & Gould PC

20070224253 - Transdermal delivery of meptazinol: A delivery system for the delivery of a salt of meptazinol or meptazinol precursor which increases the bioavailability of meptanizol by an effective amount to provide analgesic relief is disclosed. One embodiment of the delivery system is a transdermal device which increases the skin flux of meptazinol by an effective... Agent: Frommer Lawrence & Haug

20070224257 - Brucellosis dna vaccine: Brucellosis is a disease caused by facultative intracellular bacteria of the monospecific genus Brucella melitensis. The invention in one aspect is an immunogenic nucleic acid composition comprising DNA encoding Brucella melitensis Invasion Protein B, a polypeptide with at least 95% identity thereto, or an immunologically active fragment of either of... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070224256 - Apoptosis-mimicking synthetic entities and use thereof in medical treatment: Synthetic and semisythetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed... Agent: Foley & Lardner LLP

20070224255 - Liposomal formulations: The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.... Agent: Sheridan Ross PC

20070224259 - Anti-inflammatory pharmaceutical composition: The present invention provides an orally administrable capsule comprising at least two mini-tablets, or at least two mini-capsules, or a combination of at least a mini-tablet and a mini-capsule, wherein one of said mini-tablet or mini-capsule comprises a nonsteroidal anti-inflammatory drug and the other mini-tablet or mini-capsule comprises a prostaglandin.... Agent: Dr. Reddy's Laboratories, Inc.

20070224258 - Dosage forms having a randomized coating: A pharmaceutical dosage form is provided comprising a core and a shell adherent thereto, wherein the shell is comprised of at least a first portion and a second portion, each of which is compositionally distinct from each other and arranged in a randomized pattern, such as swirled or marbled. In... Agent: Philip S. Johnson Johnson & Johnson

20070224261 - Eutectic liquid drug formulation: A drug formulation dosage is provided that includes an oral medication capsule inclusive of the eutectic liquid at room temperature. The eutectic liquid includes a pharmaceutically active substance that exists as a solid in pure form at room temperature along with a biologically tolerated compound that forms a eutectic liquid... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070224260 - Dosage form having polymorphic stability: Mini-tablets comprising a drug substance are formed by compression, using forces sufficiently low to preserve the polymorphic form of the drug. The mini-tablets can be administered directly, filled into capsules, etc.... Agent: Dr. Reddy's Laboratories, Inc.

20070224263 - Aminoalkylphosphonates and related compounds as edg receptor agonists: n

20070224262 - Solid dosage form of wetted heparin: The present invention relates to a solid pharmaceutical composition (such as a solid dosage form) comprising a delivery agent and wetted heparin. The inclusion of wetted heparin rather than un-wetted heparin in the solid pharmaceutical composition results in increased delivery of the heparin. Without being bound by any particular theory,... Agent: Emisphere Technologies, Inc

20070224264 - Remote control release of encapsulated material: The present invention relates to a method for remote control release of encapsulated substances by external forces such as ultrasound or light.... Agent: Fulbright & Jaworski, LLP

20070224266 - Descarbonylethoxyloratadine containing pharmaceutical composition: A pharmaceutical composition wherein the pharmaceutically active ingredient (i.e. drug component) comprises Descarbonylethoxyloratadine and which further comprises an acidic element and a pharmaceutically acceptable stabilizer element.... Agent: Bcf LLP 25th Floor

20070224267 - Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity: The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070224268 - Process for preparing oral calcium compositions: A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μm, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii)... Agent: Bacon & Thomas, PLLC

20070224265 - Tablet comprising branched chain amino acid and method for producing the same: According to the present invention, with an object to provide a tablet comprising a branched chain amino acid that can be produced without compression molding failures and a method for producing the same, provided are a tablet comprising a branched chain amino acid and hydrogenated palatinose, a method for producing... Agent: Fitzpatrick Cella Harper & Scinto

20070224269 - Controlled release pharmaceutical formulation: The invention proves a novel compressed tablet of a pharmaceutical compound and a method of making a tablet of a pharmaceutical compound which are based on uncoated pellets containing a pharmaceutical compound that are dispersed in a matrix which comprises said pellets and a swellable polymer which is compressed into... Agent: Hedman & Costigan P.C.

20070224270 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070224271 - Healing powder and method of use thereof: A wound healing powder, comprising a sugar selected from the group consisting of one or more pharmaceutically acceptable monosaccharides and disaccharides, in an amount of at least 25% by weight of the powder mixture; and an absorbent agent which forms a bioabsorbable biocompatible matrix with wound secretions, comprising a polymer... Agent: Milde & Hoffberg, LLP

20070224272 - Method and composition for burned skin: The present invention is directed to the use of an agent selected from ethyl alcohol, isopropyl alcohol or a mixture thereof and a topically acceptable polymeric carrier in the preparation of a composition for the treatment of burns.... Agent: Nixon & Vanderhye, PC

20070224273 - Multifunctional supramolecular hydrogels as biomaterials: The present invention provides supramolecular hydrogels having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof.... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070224276 - Dry powder pharmaceutical composition, its preparation process and stable aqueous suspension obtained from such composition: Pharmaceutical composition in a dry powder form comprising at least one hydrophobic active principle, at least one water-soluble excipient and at least one surfactant, wherein the particles in said dry powder state have a Volume Mean Diameter VMDd greater than the Volume Mean Diameter VMDw of particles in a suspension... Agent: Jacobson Holman PLLC

20070224277 - Hyaluronic acid-based cross-linked nanoparticles: Methods are disclosed for preparing novel biodegradable cross-linked nanoparticles based on covalently cross-linking modifications of hyaluronic acid. The final products of the present invention are stable in aqueous media, and may be used as detergents and as additives for pharmaceutical compositions for drug delivery, DNA carrier system and other applications.... Agent: Attn: Thomas A. O'rourke Bodner & O'rourke

20070224278 - Low immunogenicity corticosteroid compositions: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes or into a joint are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at... Agent: Allergan, Inc.

20070224274 - Polymer particles containing active agents: The invention relates to active ingredient-containing polymer particles comprising a vinyl polymer from 10-80% by weight monomers comprising amino and/or carboxyl groups, which is insoluble in one part of the pH range 0-10 and is soluble in another part of the range, wherein these active ingredient-containing polymer particles comprise 3-1000... Agent: Hutchison Law Group PLLC

20070224275 - Selenium-based biocidal formulations and methods of use thereof: Biocidal formulations that include a selenium compound selected from the group consisting of RSeH, RSeR, RSeR′, RSeSeR, RseSeR′, and RseX, wherein each of R and R′ is an aliphatic or phenolic residue, and wherein X is a protecting group selected from the group consisting of a halogen, an imide, a... Agent: Dunlap, Codding & Rogers P.C.

20070224279 - Stabilization of chemical compounds using nanoparticulate formulations: Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070224280 - Novel nanoparticles for delivery of active agents: Milled nanoparticles comprising a biolgically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications... Agent: Glenna Hendricks, Esq.

20070224281 - Sustained-release preparations containing topiramate and the producing method thereof: Disclosed herein is a sustained-release topiramate preparation and a method for producing the topiramate preparation. The sustained-release topiramate preparation is produced using double granules obtained by granulating topiramate or a pharmaceutically acceptable salt thereof using a solid dispersant by a solid dispersion method (first granulation), and further by granulating the... Agent: Heslin Rothenberg Farley & Mesiti PC

20070224282 - Fine dispersion of sparingly soluble drug and process for producing the same: An effective and simple process for producing a fine dispersion of a poorly soluble drug; and a fine sparingly-soluble-drug dispersion having excellent dispersion stability. In a first step, a poorly soluble drug is suspended in a liquid containing no deflocculant and the suspension is subjected to a high-pressure treatment with... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070224283 - Pharmaceutical compositions comprising crosslinked amine polymer with repeat units derived from polymerization of tertiary amines: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers (ilps)

20070224284 - Methods and compositions comprising at least one alpha3 beta4 nachr antagonist or pharmaceutically acceptable salt thereof: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070224285 - Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing... Agent: Sughrue Mion, PLLC

20070224286 - Process for preparing calcium phosphate self-setting bone cement, the cement so prepared and uses thereof: A calcium phosphate self-setting cement is invented by using diffusion controlled solid liquid heterogeneous reaction between tetracalcium phosphate (Ca4(PO4)2O, TTCP) fine powder and solution of di-potassium hydrogen phosphate (K2HPO4). Fine powders of tetracalcium phosphate is introduced into the di-potassium hydrogen phosphate solution and homogenized well to form a cement paste.... Agent: Dewitt Ross & Stevens S.c.

20070224287 - Methods of modulating inflammatory reactions by modulating xanthine oxidoreductase activity: Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR... Agent: Morgan Lewis & Bockius LLP

20070224288 - Antibacterial gel coating and pedicure spa with antibacterial function: A pedicure spa with antibacterial function includes a tub having a surface and a gel coating on the surface of the tub. The gel coating includes an industrially applicable gel coating mixed with silver nano-particles having a diameter in the range of approximately 10-35 nm such that a concentration of... Agent: Cohen, Pontani, Lieberman & Pavane

20070224289 - Multi-component biocide composition for wood protection: The present disclosure generally relates to a multi-component biocide composition comprising a borate component in combination with an azole component to both inhibit mold fungi, decay fungi, such as brown-rot fungi and white-rot fungi, and to resist insect infestation.... Agent: Janet I. Stockhausen Usda Forest Service

20070224290 - Nutrient supplements and methods for treating autism and for preventing the onset of autism: Provided by the present invention are novel and non-obvious nutrient supplements that preferably comprise minerals, vitamins, amino acids, and agents capable of delivering cysteine in vivo. The nutrient supplements desirably are capable of promoting metallothioneins, and optionally, promoting the removal of excess metals from the bloodstream. Also provided by the... Agent: Merchant & Gould PC

20070224291 - Cancer treatment: A composition and method for treating mammals suffering from malignant tumors which involves administering a composition including ammoniated mercury, zinc oxide and citric acid.... Agent: Abelman, Frayne & Schwab

20070224292 - Extended effect ergogenic drink: An extended energy drinkable beverage composition includes: caffeine, chromium in the form of chromium polynicotinate, niacin and the electrolytes calcium, potassium, magnesium, sodium, and the nutrient Vitamin C. The invention also relates to a method to use the composition, with the following effects: increased mental alertness, decreased fatigue, improved aerobic... Agent: The Law Office Of Randall T. Erickson, P.C.

20070224293 - Virus-interacting layered phyllosilicates and methods of inactivating viruses on animate and inanimate surfaces: Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses. Accordingly, provided herein is a method of inhibiting transfer of a virus to a surface comprising contacting the surface with a composition comprising a layered phyllosilicate material in an amount sufficient for inhibiting the transfer of the... Agent: Marshall, Gerstein & Borun LLP

20070224294 - Novel non-surgical method for treating cataracts in mammals including man: An anti-oxidant cocktail demonstrated efficacious in the treatment of avian and mammalian cataracts, useful for veterinary and human use as a veterinary or human pharmaceutical (to cure existing cataracts) or as a dietary supplement (to maintain a healthy, non-diseased state).... Agent: Pharmaceutical Patent Attorneys, LLC

20070224295 - Compositions using evaporable silicone carriers for cosmetics, cleaning and care product compositions: where R1 and R2 are selected from the group of linear or branched monovalent hydrocarbon radicals having from one to eight carbon atoms and where each R3, R4, R5, R6, and R7 is independently selected from the group of monovalent hydrocarbon radicals having from one to sixty carbon atoms; and... Agent: Momentive Performance Materials Inc.IPLegal

20070224296 - Transcription modulator compositions: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of IκB kinase subunit α activity. The composition can also be administered to a subject at high risk for prostate... Agent: Occhiuti Rohlicek & Tsao, LLP

20070224297 - Method for increasing content of physiologically active substance in ginseng: The present invention relates to a method for economically preparing ginseng extract having an increased content of physiologically active substances, comprising the steps of steaming ginseng at 95 to 100° C. for 1 to 24 hours, collecting the generated vapor by cooling, and repeating the process twice, to a composition... Agent: O'keefe, Egan, Peterman & Enders LLP

20070224298 - Inhibiting 11(beta)-hsd1 with citrus flavonoids: A therapeutically effective dose of polymethoxylated flavones, for example in the form of citrus peel extract, is provided for reducing the activity of 11(beta)-HSD1. Reducing the activity of 11(beta)-HSD1 in turn undesirable excess glucocorticoid, e.g. cortisol, levels. Particularly, the PMFs can be effectively used to inhibit a rise in glucocorticoids... Agent: Holme Roberts & Owen, LLP

20070224300 - Weight loss compositions using citrus peel extract and eurycoma longfolia: A combination of Eurycoma longifolia and citrus peel extract are provided in a supplement to promote weight loss and help dieters maintain high energy levels by reducing the body's normal shift to a catabolic state during weight loss. The Eurycoma longifolia root extract preferably includes eurypeptides and the citrus peel... Agent: Holme Roberts & Owen, LLP

20070224299 - Weight loss with citrus flavonoids: A therapeutically effective dose of polymethoxylated flavones, for example in the form of citrus peel extract, is provided for reducing the typical rise in cortisol levels in a mammal undergoing weight loss. The polymethoxylated flavones may include one or more of tangeretin, nobiletin, and sinensetin. The polymethoxylated flavones may be... Agent: Holme Roberts & Owen, LLP

20070224301 - Compounds from an extract of artemisia and methods for treating disorders: This invention comprises an extract of Artemisia dracunculus that can be used for the treatment and prevention of diabetes, diabetic complications, metabolic syndrome and other comorbidities that share the underlying commonality of insulin resistance. The invention includes the identity of six compounds from the extract that contribute to the activity... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070224302 - Maintaining anabolic hormone profile during weight loss and intense exercise: Eurycoma longifolia is used for reducing cortisol levels and raising testosterone levels in persons under stress. A method for promoting weight reduction includes administering to a human having a caloric deficit an effective dose of Eurycoma longifolia for reducing cortisol levels and raising testosterone levels relative to respective cortisol and... Agent: Holme Roberts & Owen, LLP

20070218014 - Cosmetic or pharmaceutical product for topical use: The components are dispensed on the body surface to be treated from a pressurized vessel. The propellant evaporates from liquid to gaseous as it exits from the pressurized vessel and upon contact with the body surface to be treated, forms gas bubbles in the gel. The bursting of these bubbles... Agent: Modiano & Associati

20070218021 - Non-irritating sunscreen composition: An oil in water emulsion based sunscreen composition incorporating inorganic sunscreen agents is provided. The sunscreen composition is non-irritating to the eyes and mucous membranes.... Agent: Kelly Lowry & Kelley, LLP

20070218032 - B7-h4 expression on tumor vasculature: Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described.... Agent: Fish & Richardson P.C.

20070218038 - Stabilized, sterilized collagen scaffolds with active adjuncts attached: Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is... Agent: Wilson Sonsini Goodrich & Rosati

20070218046 - Method of enhancing degradation of chitin: The present invention provides a method of enhancing chitin degradation or weakening the structure of a chitin substrate comprising exposing chitin to a non-hydrolytic chitin binding protein (CBP). The invention further provides a method of enhancing chitin degradation comprising exposing chitin to a non-hydrolytic CBP and a chitin hydrolase. Compositions,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070217996 - Activatable particles, preparations and uses: The present invention relates to novel activatable particles which can be used in the health sector. The invention more particularly relates to composite particles which can generate free radicals or heat when excited by X rays, and to the uses thereof in health, particularly human. The inventive particles comprise an... Agent: Nixon & Vanderhye, PC

20070217997 - Metalloproteinase binding proteins: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.... Agent: Fish & Richardson PC

20070217998 - Locoregional internal radionuclide ablation of abnormal tissues: The present disclosure provides methods of using unsealed and non-colloidal radiopharmaceuticals, for example beta emitting radiopharmaceuticals such as Yttrium-90 chloride, Indium-111 chloride, F-18-2-deoxy-2-fluoro-D-glucose, or combinations thereof, for locoregional ablation of cells in the abnormal tissue.... Agent: Vinson & Elkins, L.L.P.

20070218001 - Biotherapeutics, diagnostics and research reagents: The present invention provides polypeptides that contain one or more PDZ domains and are useful in the detection of pathogens. The polypeptides of the invention are also useful in the diagnosis, treatment, and prevention of diseases. Also provided are methods of preparing polypeptides of the invention.... Agent: Fish & Richardson PC

20070217999 - Excretable reporter systems: The present invention provides a reporter system comprising a reporter gene encoding a reporter protein that is secretable from cells in which it produced or expressed either in vitro or in vivo and excretable in a body fluid from whole animals comprising such systems. The reporter system is useful for... Agent: Myers Bigel Sibley & Sajovec

20070218002 - Method for detecting alzheimer's disease and other forms of dementia, and measuring their progression: The invention provides a method for detecting or monitoring Alzheimer's disease and other forms of dementia using positron emission tomography (PET) or single-photon emission computed tomagraphy (SPECT) and radiolabeled, serotonin 5-HT1A receptor-specific tracers (such as [F-18]MPPF, [F-18]FCWAY, [C-11]WAY-100635, and other radiolabeled compounds having agonistic or antagonistic effect on serotonin receptors),... Agent: Christie, Parker & Hale, LLP

20070218000 - Protein nmb1125 and use thereof in pharmaceutical formulations: In order to achieve this goal the NMB1125 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally, the gene codifying for NMB1125 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in... Agent: Hoffmann & Baron, LLP

20070218004 - Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpesviruses: A vertical mother-progeny transmission route of human herpesviruses has been discovered that allows developing an animal model that is useful for identifying compounds that are potentially useful in treating and/or preventing infections and diseases caused by human herpesviruses. The method for identifying such compounds comprises experimentally infecting a non-human female... Agent: Moore & Van Allen PLLC

20070218005 - Nuclei density and nuclei area methods for determining the effects of a botulinum toxin on muscles: Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In... Agent: Allergan, Inc.

20070218003 - Truncated dance, dance complex and method of using these: The present invention provides a screening method that enables the development of a pharmaceutical of a new mechanism of action allowing the regulation of the formation of elastic fibers, and various means necessary for the method. More specifically, the present invention provides a polypeptide obtained by cleaving DANCE and a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070218006 - Method for monitoring early treatment response: Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the cancerous tissue before and after treatment; the treatment comprises administration of a cell surface receptor inhibitor, for example, an... Agent: Leydig Voit & Mayer, Ltd

20070218009 - Lanthanide rich nanoparticles, and their investigative uses in mri and related technologies: An aqueous soluble, lanthanide rich nanoparticle for investigative use, such as NMR, MRI, CT, PET, and GdNCT is provided. The nanoparticle is synthesized from a mixture comprising lanthanide ions and coated with a suitably selected organic ligand such that the resultant nanoparticle is soluble in aqueous solutions. A method of... Agent: Klarquist Sparkman, LLP

20070218008 - Svct2 transporters expressed in blood brain barrier cells: SVCT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the SVCT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in... Agent: Townsend And Townsend And Crew, LLP

20070218010 - Contrast agents for magnetic resonance imaging: The invention relates to contrast agents for magnetic resonance imaging comprising a chelating ligand and a transition metal ion, said ligand carrying a substituent capable of reacting chemically or biochemically with a target substance while bringing about a change in the spin state.... Agent: Buchanan, Ingersoll & Rooney PC

20070218007 - Ophthalmic visualization compositions and methods of using same: Compositions and methods useful for at least assisting in visualizing vitreous bodies of eyes of humans or animals are provided. Such compositions include a contrast component and a carrier component and are substantially free of any therapeutic agent effective to have pharmacological activity in an eye in which the composition... Agent: Stout, Uxa, Buyan & Mullins LLP

20070218011 - Aerosol formulation comprising formoterol in suspension: A pharmaceutical aerosol formulation comprising formoterol fumarate di-hydrate in suspension, and a steroid in solution, and a propellant, ethanol, and optionally a surfactant, wherein the formoterol fumarate di-hydrate has a water content of about 4.8 to 4.28% by weight, more particularly about 4.5 to 4.28%.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070218012 - Pharmaceutical compositions: Methods of spray drying are described.... Agent: Fish & Richardson PC

20070218013 - Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070218015 - Tooth-whitening composition: A tooth-whitening composition is provided, comprising at least one whitening agent together with at least one filin forming material, such that the composition is in the form of a film which is water soluble and/or water-dispersible. This has the advantages of not requiring a separate carrier material during use, and... Agent: Hoffmann & Baron, LLP

20070218016 - Use of aroma substance mixtures as agents against bad breath: Mixtures comprising (a) eugenol acetate and isoeugenol methyl ether of (b) eugenol acetate and beta-homocyclocitral or (c) eugenol acetate, isoeugenol methyl ether and beta-homocyclocitral are described. The use of these mixtures as agents against bad breath is furthermore described.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070218017 - Induced remineralisation of human dental enamel: The present application relates to the induced remineralization of human tooth enamel and in particular to the building up of apatite on tooth material.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070218018 - Sensitivity relief gel: The present invention provides a sensitivity relief gel preferably for use following a dental treatment such as a whitening session. The relief gel contains at least one desensitizing agent, at least one source of fluoride and at least one gelling agent. The relief gel has reduced gumminess and is easy... Agent: Discus Dental Impressions, Inc.

20070218020 - Composition and method for providing protection from dermatitis, from urushiol and/or from sunlight: A formula and a method provide protection from dermatitis, from urushiol and/or from sunlight. The formula and/or a composition has an ultra-violet reflective ingredient, a preservative and/or a moisturizer to protect skin of a user from the dermatitis, the sunlight and/or urushiol. The formula and/or the composition is applied to... Agent: Patents+tms A Professional Corporation

20070218022 - Photostable sunscreen compositions comprising cinnamic acid ester uv-b filters, dibenzoylmethane uv-a filters and s-triazine compounds: Photostable sunscreen compositions containing at least one cinnamic acid ester UV-B screening agent, at least one dibenzoylmethane compound UV-A screening agent and at least one particular s-triazine compound have improved effectiveness with respect to UV-B radiation, while maintaining the balance in UV-A/UV-B protection during exposure to the sun.... Agent: Buchanan, Ingersoll & Rooney PC

20070218019 - Surface-modified metal oxides methods for production and use thereof in cosmetic preparations: The present invention relates to surface-modified nanoparticulate metal oxides, methods for their production and use thereof as UV filters in cosmetic preparations.... Agent: Connolly Bove Lodge & Hutz, LLP

20070218023 - Uses of melatonin in skin: Melatonin, which can be produced in the skin, exerts a protective effect against damage induced by ultraviolet radiation (UVR). The present study investigated the effect of UVB, the most damaging component of UVR, on melatonin metabolism in HaCaT keratinocytes and in a cell-free system. Four metabolites were identified by HPLC... Agent: Dr. Benjamin Adler Adler & Associates

20070218024 - Dry water cosmetic compositions that change color upon application: A powdered water cosmetic composition comprising activatable pigments, a water phase comprised of water droplets, and a particulate phase comprised of non-wetting particulates operable to surround and sequester the individual water droplets from each other in the composition, wherein said activatable pigments prior to activation provide a composition having a... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070218025 - Aqueous anti-perspiration formulation: The invention relates to a cosmetic formulation with improved effectiveness and reduced stickiness, comprising at least one activated aluminum antiperspirant active ingredient, at least one alpha-hydroxycarboxylic acid and water.... Agent: Greenblum & Bernstein, P.L.C

20070218026 - Dna encoding the human serine protease eos: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease... Agent: Philip S. Johnson, Esq. Johnson & Johnson

20070218028 - Hair-treating agent and methods of treating hair: r

20070218027 - Process for relaxing or straightening hair: A process for straightening or relaxing hair involving the steps of: (a) contacting the hair with the above-disclosed hair straightening/relaxing composition to form treated hair; (b) optionally, rinsing the hair straightening/relaxing composition from the treated hair, after it has been in contact with the hair for a period of less... Agent: L'oreal Usa/ Patent Department

20070218029 - High-deposition compositions and uses thereof: Provided are compositions comprising actives associated with cationically-charged delivery systems, which compositions tend to exhibit relatively high-deposition of the actives onto the skin, nails, vagina and/or hair upon application thereto, and methods of use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070218030 - Dietetic preparation for prevention and treatment of osteoporosis: The present invention relates to a dietetic preparation containing at least one physiologically acceptable salt of hyaluronic acid having molecular weight from 500 000 to 4 000 000 g/mol, which is in the form suitable for oral administration formulated into tablets, chewing tablets, jelly capsules, an instant drink, a chewing... Agent: Wood, Herron & Evans, LLP

20070218031 - Agent for prevention and/or treatment of alzheimer's disease: The present invention provides a novel drug/agent for the prevention and/or treatment of Alzheimer's disease based on a different Alzheimer's disease onset mechanism from the amyloid hypothesis, and a method of screening for it.... Agent: Fitch, Even, Tabin & Flannery

20070218033 - Composition and method of treating hepatitis c: Compositions and methods of use for treating hepatitis C virus-infected mammals are disclosed. The compositions include one or more thymosins in combination with one or more interferons. Methods of treatment include use of thymosins together, or sequentially with interferon.... Agent: Nash & Titus, LLC

20070218034 - Methods of using hcn genes to treat cardiac arrhythmias: The subject invention is directed to methods of treating cardiac pacing dysfunction by administering HCN genes, alone or in combination with other genes.... Agent: Carol M. Nielsen Winstead PC

20070218035 - Use of live bacteria for growth promotion in animals: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those... Agent: Patent Group Choate, Hall & Stewart

20070218036 - Method for the prevention of infection with nodavirus and method for the treatment thereof: The present invention provides a method for the prevention or the treatment of an infection of fishes with nodaviruses or a disease such as, for example, viral nervous necrosis or the like, caused by an infection with nodaviruses. The infection of fishes with nodavirus or the outbreak of a disease... Agent: Jordan And Hamburg LLP

20070218037 - Therapeutic agent for fibromyalgia: A therapeutic agent for fibromyalgia containing an extract from inflamed tissue inoculated with vaccinia virus as an active ingredient, use of the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises... Agent: Oliff & Berridge, PLC

20070218039 - Conjunctival tissue system: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a... Agent: Vinson & Elkins, L.L.P.

20070218041 - Topical composition having undifferentiated plant seed cells and method for using same: There is disclosed a topical composition having substantially undifferentiated plant seed cells and, preferably, a pharmaceutically or cosmetically acceptable vehicle. There is also a method for topically applying the composition. There are also methods for delivering a consistent level of an active to skin, nail, lips and/or hair and for... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20070218040 - Urinary tract tissue graft compositions and methods for producing same: A method for providing a urinary tract tissue graft composition includes providing a segment of small intestinal submucosa and isolating and culturing at least one multipotent cell type from a tissue specimen of a subject. The at least one multipotent cell type is then seeded upon a surface of the... Agent: Dunlap, Codding & Rogers P.C.

20070218044 - Decomposition and modification of silicate and silicone by silicase and use of the reversible enzyme: Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070218042 - Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia.... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070218043 - Use of a compound for enhancing the expression of membrane proteins on the cell surface: The present invention is directed to the use of a compound stimulating deubiquitinating activity in a cell for the manufacture of a medicament for enhancing the expression of integral membrane proteins on the cell surface. Especially, the invention is directed to the use of such compound for the manufacture of... Agent: Fitzpatrick Cella Harper & Scinto

20070218045 - Skin treatment preparation: A skin treatment preparation including carriers, a medicinal vector encapsulating a plant extract (Cucumis melo protein extract) rich in reductase, catalase and superoxide dismutase is characterized in that the medicinal vector, of nanospheres, represents 1 to 20 wt. % of the weight of the preparation; and the encapsulated plant extract... Agent: Oliff & Berridge, PLC

20070218047 - Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2): The invention provides a human KLK2 which is associated with the hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological... Agent: Banner & Witcoff, Ltd.

20070218050 - Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear: Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a chemical penetration enhancer, such as propylene glycol and gluconolactone. The compositions are applied to the ear so as to contact the outer surface of an intact tympanic membrane to deliver the medicament... Agent: Dla Piper US LLP

20070218049 - Nanoparticle based photodynamic therapy and methods of making and using same: A novel method for cancer treatment that combines radiotherapy and photodynamic therapy (PDT). More particularly, luminescent nanoparticles with attached photosensitizers, such as porphyrins, are used as a new type of agent for photodynamic therapy. Upon exposure to ionizing radiation, light will emit from the nanoparticles to activate the photosensitizers; as... Agent: Dunlap, Codding & Rogers P.C.

20070218048 - Sfec, a sperm flagellar energy carrier protein: The present invention is directed to a sperm flagellar energy carrier, SFEC, antibodies specific for the SFEC and the use of the SFEC protein to identify antagonists of SFEC activity. SFEC is believed to be essential for sperm motility, is localized to a specific region of the sperm, and thus... Agent: University Of Virginia Patent Foundation

20070218051 - Epitope peptides immunogenic against streptococcus pneumoniae: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the... Agent: Needle & Rosenberg, P.C.

20070218053 - Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor agonist... Agent: Catalyst Law Group, Apc

20070218054 - In vitro germinal centers: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an... Agent: Merchant & Gould PC

20070218052 - Novel lgg3 antibodies for stimulating phagocytosis: The invention relates to human or humanised, chimeric, monoclonal, class IgG3 antibodies produced in a cell line of rat myeloma, especially line YB2/0. Said antibodies have a strong phagocytosis activity and can be administered for the treatment of cancers and infections.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070218055 - Ferroportin1 nucleic acids and proteins: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070218056 - Methods for identification, diagnosis, and treatment of breast cancer: The invention provides methods of identifying premalignant and malignant breast cancer, determining lymph node involvement in patients diagnosed with premalignant and malignant breast cancer growths, and methods of treating premalignant and malignant breast cancer. The diagnostic and methods comprise intraductal administration of a targeting molecule either alone acting as an... Agent: Cytyc Corporation

20070218057 - Human obesity susceptibility gene and uses thereof: The present invention discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MAP3K11 gene on chromosome 11 and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070218058 - Methods for inducing autolysis in infectious bacteria: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacter cells, and preventing virulence or restoring a benign state in surviving cells. These... Agent: Pepper Hamilton LLP

20070218059 - Cell surface marker: The present invention provides a cell marker that is characterized by binding to a GCTM-5 antibody of active fragment. The cell marker identifies a unique sub-population of stem cells that show characteristics of hepatic or pancreatic stem cells or hepatic or pancreatic progenitor cells. More specifically the marker is an... Agent: Nixon Peabody LLP - Patent Group

20070218060 - Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma: Methods of therapy for treating a subject for multiple myeloma are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but... Agent: Alston & Bird LLP

20070218061 - Use of ephrinb2 directed agents for the treatment or prevention of viral infections: In certain embodiments, this present invention provides EphrinB2-targeted agents, including polypeptide compositions and nucleic acid compositions for the treatment or prevention of infections by viruses of the family Paramyxoviridae.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070218062 - Methods of treating lupus using cd4 antibodies: Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody... Agent: Quine Intellectual Property Law Group, P.C.

20070218065 - Antibodies that bind both il-17a and il-17f and methods of using the same: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same... Agent: Zymogenetics, Inc. Intellectual Property Department

20070218064 - Human anti-il-23 antibodies, compositions, methods and uses: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20070218063 - Method and composition for treatment of renal disease with antibodies and their equivalents: A method for treating renal disease includes administering to a patient suffering from renal disease an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can... Agent: Houston Eliseeva

20070218067 - Antibody of human origin for inhibiting thrombocytes aggregation: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.... Agent: Howrey LLP

20070218068 - Human autism predisposition gene encoding a transcription factor and uses thereof: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and... Agent: Fish & Richardson PC

20070218069 - Methods and compositions for targeting polyubiquitin: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.

20070218066 - Tropomyosin isoforms, and diagnostic and therapeutic uses therefor: A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed... Agent: Licata & Tyrrell P.C.

20070218070 - Methods of modulation of the immune system: Manipulation of the EphB6 receptor and its active Eph partners allow for regulation of T cell responses, including TCR signalling, T cell proliferation, and induction of T cell death. Methods of modulating EphB6 are described as well as various therapeutic applications.... Agent: Jagtiani + Guttag

20070218071 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Lisa E. Alexander Sagres Discovery, Inc.

20070218073 - Antigenic composition: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.... Agent: Mark B. Wilson Fulbright & Jaworski L.L.P.

20070218072 - Methods of improving health-related quality of life in individuals with systemic lupus erythematosus: The invention provides methods for stabilizing or improving the health-related quality of life in individuals with SLE, and methods of selecting individuals suitable for such treatment. One method of stabilizing or improving the health-related quality of life of an individual with SLE involves the administration of an effective amount of... Agent: Morrison & Foerster LLP

20070218074 - Hpv vaccine comprising peptides from host cell proteins: The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host... Agent: King & Schickli, PLLC

20070218075 - Altered fibronectin-binding protein of staphylococcus aureus: An isolated, altered fibronectin-binding protein (Fnb) of S. aureus having at least one mutation in an amino acid selected from residues corresponding to Gln103, Gln105, Lys157, Lys503, Lys620, Lys702, Lys762, Gln783 and Gln830 of FnbA of S. aureus strain ATCC49525 is described. Replacement of these reactive residues within the fibronectin-binding... Agent: Wyeth Patent Law Group

20070218076 - Method of processing seaweed: A method of processing seaweed, preferably a brown seaweed, comprises the following steps: (I) treating seaweed with an alcohol having one to six carbon atoms, preferably ethanol, to form an alcoholic fraction and an insoluble first seaweed residue; (II) separating the alcoholic fraction; (III) removing the alcohol from the alcoholic... Agent: Morgan Lewis & Bockius LLP

20070218077 - Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response: A method for delivering a naked or isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of a naked polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070218078 - Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof: The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070218079 - Method to induce rnai in prokaryotic organisms: The present invention relates to a method for regulating the expression of a target gene in a prokaryotic cell and a horrigent suitable for conducting the method.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070218080 - Peptide antigen of human papillomavirus type 16 and application thereof: Disclosed is a HPV-16 peptide antigen, and the antigen comprises a peptide sequence of SEQ ID No: 1. The peptide antigen of the invention is able to bind with MHC class I antigen on the cell and be presented on the cell surface. It can be recognized by cytotoxic T... Agent: Morris Manning Martin LLP

20070218081 - Adipogenic adenoviruses as a biomarker for disease: This invention relates to the relationship between infection with adipogenic adenoviruses, such as adenovirus-36 (Ad-36) and the etiologies of obesity and obesity-related cancers and other diseases. Additionally, the invention relates to assaying a subject for Ad-36 status and using Ad-36 status as a marker for the presence of cancer, to... Agent: Mcguirewoods, LLP

20070218082 - P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.... Agent: Fulbright & Jaworski, L.L.P.

20070218083 - Methods for facilitating weight loss: The present invention provides methods for facilitating weight loss in a patient. In some embodiments, the methods comprise the steps of locally administering a botulinum toxin to a stomach tissue of an obese patient, and deploying a gastric band around the stomach of the patient.... Agent: Allergan, Inc.

20070218085 - Botulinum toxin therapy for neuropsychiatric disorders: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.... Agent: Allergan, Inc.

20070218084 - Method for the mapping of the epileptogenic focus in the pre-surgical evaluation of patients with intractable epilepsy: A method for functionally identifying an epileptogenic focus in pre-surgical evaluation in affected subjects with intractable epilepsy is described, the method including the delivery of an effective dose of a botulinum neurotoxin (BoNT) to a presumptive epileptogenic focus in the disease-compromised central nervous system of a mammal, under conditions whereby... Agent: Akerman Senterfitt

20070218086 - Adjuvant composition and methods for its use: The present invention is directed to a vaccine adjuvant which improves the vaccine potency. More specifically, the present invention is directed to the use of a γδT lymphocyte activator as vaccine adjuvant to promote and enhance antigen specific immunological responses, as well as a vaccine composition comprising a γδT lymphocyte... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070218087 - Method of controlled release of vanillin for nasal and/or pulmonary uptake: A gaseous vanillin compound is continuously released for nasal and/or pulmonary uptake. The gaseous vanillin compound is provided in a patch having a layer that is impermeable to the gaseous vanillin compound, a layer permeable to the gaseous vanillin compound, and the vanillin localized between the two layers. The patch... Agent: Lerner Greenberg Stemer LLP

20070218092 - Deodorant patch and method for making: This invention relates generally to an underarm hygiene product having the form of a deodorant patch between a top carrier sheet and a bottom carrier sheet. Deodorant patches dissolve upon contact with the underarm skin and provide a discreet, portable method of remaining fresh in any time or place. Convenient... Agent: Kevin D. Erickson Pauley Petersen & Erickson

20070218090 - Dissolvable strip for delivery of an agent: An article of manufacture includes a substrate having at least one zone on a surface of the substrate and at least one ingredient on a surface of the substrate. The at least one ingredient is associated with a respective one of the at least one zone.... Agent: Perman & Green

20070218089 - Aqueous polymer dispersion containing effect materials, method for production and use thereof: Aqueous polymer dispersions comprising effect substance and having an average particle diameter of the dispersed particles of <500 nm, where the polymer particles comprise a polymer matrix constructed from at least one ethylenically unsaturated monomer as core, on the surface of which is arranged at least partially an effect substance... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070218088 - Dentifrice composition comprising a soluble calcium sequestering agent: A dentifrice composition is disclosed comprising a soluble calcium sequestering agent that is not an oxidizing agent, wherein the composition has an RDA value of below 30 and an IVSR value greater than 50 (when compared to a Control) and an orally acceptable vehicle, wherein the calcium sequestering agent is... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070218091 - Gel with a high concentration of branched sulphonic polyester and method for preparing same: A cosmetic composition in the form of a gel with a high concentration of branched sulphonic polyester and a method for preparing said gel and using same for producing cosmetic compositions in any galenic form.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070218093 - Applicator and method for applying lanolin to a sore nipple: A lanolin application kit comprising lanolin and a lanolin applicator is used to apply lanolin to a body surface, particularly on a nipple, without leaving undesired lanolin residue on the user, and so that contamination of other unused lanolin is minimized.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070218094 - Method and trap for controlling insect pests: A method of controlling pests, such as crawling and flying insects by trapping and killing pests, comprising using organic particles, wherein the organic particles are of a composite of piperine, (C17 H19 N03), powders, the active principle of peppers, that adhere to the insects cupules and cleaving balls of pests,... Agent: Alan James Julier

20070218096 - Medical equipment and methods of making and using the same: Medical equipment for use in an operating room setting, a hospital, or any other medical facility is disclosed. Methods of making and using medical equipment are also disclosed.... Agent: Withers & Keys, LLC

20070218095 - Photocatalytic substrate with biocidal coating: A construction structure includes a structural layer having a biocidal material and an external surface. A biocidal polymeric coating layer is disposed on the external surface.... Agent: 3m Innovative Properties Company

20070218097 - Subcutaneous glucose electrode: A small diameter flexible electrode designed for subcutaneous in vivo amperometric monitoring of glucose is described. The electrode is designed to allow “one-point” in vivo calibration, i.e., to have zero output current at zero glucose concentration, even in the presence of other electroreactive species of serum or blood. The electrode... Agent: Jackson & Co., LLP

20070218099 - Preparation and characterization of polyethyleneglycol/polyesters as biocompatible thermo-sensitive materials: The present invention relates to a biocompatible and thermosensitive poly(ethylene glycol)/polyester block copolymer and a method of its preparation thereof, and particularly to a multi-functional intelligent hydrogel polymer comprising a hydrophilic part of a poly(ethylene glycol) (PEG) having a low molecular weight and a hydrophobic part comprising an ester-based caprolactone... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070218101 - System and method for percutaneously administering reduced pressure treatment using a flowable manifold: A reduced pressure delivery system for applying a reduced pressure to a tissue site includes a manifold delivery tube having a passageway and a distal end, the distal end configured to be percutaneously inserted and placed adjacent the tissue site. A flowable material is provided and is percutaneously deliverable through... Agent: Kinetic Concepts, Inc. Attn: Legal Department Intellectual Property

20070218098 - Bone formation agent and method of production: The invention relates to a bone formation agent of porous calcium phosphate having an isotropic sintered structure and, between the particles of the calcium phosphate, statistically distributed pores in a plurality of discrete size ranges. The bone formation agent has at least two, preferably three, discrete pore size distributions. Its... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070218102 - Biodegradable hydrophobic polysaccharide-based coatings: Implantable medical articles having a coating formed of hydrophobic derivatives of natural biodegradable polysaccharides are described. The coatings can include a bioactive agent, and demonstrate desirable bioactive agent release profiles and can be prepared to have high drug loading. The coated implantable medical articles can be used to treat medical... Agent: Kagan Binder, PLLC

20070218103 - Rate controlled release of a pharmaceutical agent in a biodegradable device: Matrix controlled diffusion drug delivery systems comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a copolymer which is a reaction product of a monomeric mixture comprising one or more acrylate ester and/or methacrylate ester-containing monomers and one or more acrylamido-containing monomers are disclosed. Also... Agent: Bausch & Lomb Incorporated

20070218104 - Rate controlled release of a pharmaceutical agent in a biodegradable device: Matrix controlled diffusion drug delivery systems comprising a therapeutically effective amount of one or more pharmaceutically active agents polymerized with a monomeric mixture comprising one or more acrylate ester and/or methacrylate ester-containing monomers and one or more acrylamido-containing monomers are provided. Processes for their preparation and methods of use are... Agent: Bausch & Lomb Incorporated

20070218105 - Topical treatment with ngf and dha in damaged corneas: The topical administration of a combination of nerve growth factor (NGF) and docosahexaenoic acid (DHA) has been discovered to synergistically increase the effects of NGF in re-innervating the cornea. This enhancement in corneal nerve re-growth will yield a faster anatomical and functional recovery after PRK or LASIK surgeries. Using rabbits,... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20070218108 - Lipolysis promoter and food-and-drink and feed containing the same: A naturally-derived lipolysis promoter with high safety, which may promote the degradation of the accumulated adipose tissue to control, prevent, and ameliorate obesity to a satisfactory extent, and food-and-drink and feed containing the same containing at least one or more kinds of plants selected from the group consisting of plants... Agent: Scott R. Cox Lynch, Cox, Gilman & Mahan, P.s.c.

20070218110 - Novel enhanced process for imparting therapeutic and nutritive levels of flaxseed to mammals: A process for imparting healthful dosages of flaxseed to mammals and a muffin-based regimen for providing a healthful and therapeutic dosage of Alpha-Linolenic Acid (ALA), an essential omega-3 fatty acid, in combination with desiderata selected from the group consisting of cinnamon, fiber, bananas, walnuts, carrots—optionally, without any negative impact upon... Agent: Greenberg Traurig LLP (la)

20070218111 - Strontium compositions for bones: A composition of matter includes an effective amount of strontium carbonate for affecting bone metabolism. The composition is substantially free of calcium to avoid absorption competition in the digestive tract. The composition is also preferably substantially free of chelating agents, phosphate, phytic acid, oxalates, insoluble fibers, and non-strontium divalent cations... Agent: Holme Roberts & Owen, LLP

20070218112 - Agent and food for preventing / improving functional digestive disorder: The present invention provides an agent and a food for the prophylaxis or improvement of a functional gastrointestinal disorder, which contains, as an active ingredient, at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070218106 - Alcohol metabolism moderating composition: The present invention is directed to a composition, in particular a food composition, or dietary supplementation which is active in respect to the support and/or the moderation of an alcohol degradation process within the human body. The present invention particularly addresses the problem of rapid alcohol degradation i.e. alcohol metabolism... Agent: Fulbright & Jaworski L.L.P.

20070218113 - Health bars and compositions for improving cardiovascular risk factors: The invention provides, in one aspect, a method of administering a product comprising beta glucan, soy protein, phytosterols, and an omega-3 fatty acid, such as one or more of DHA and EPA, to improve cardiovascular risk factors, such as LDL levels or total cholesterol levels. The amount of each of... Agent: Wiley Rein LLP

20070218107 - Method of dieting and tools for implementing same: The inventive diet is designed to provide an easy and effective meal plan to assist an individual to meet his/her dietary goals. The dieter consumes about four meals per day, wherein the total daily caloric content of the meals comprises about 45% carbohydrates selected from fiber rich foods containing at... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070218109 - Nutrient composition and composition for prevention/mitigation of digestive tract depression: As a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which improve lower gastrointestinal function and are effective for the prophylaxis or improvement of diarrhea, gastroesophageal reflux or misswallowing caused by administration of a liquid nutritional supplement, the present invention provides a nutritional composition... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070218114 - Soluble strip for oral or topical administration: A composition for oral administration comprising at least one active ingredient including at least one active ingredient having activity in reducing the effect of conditions of the throat or throat disorders, distributed within a soluble base material, the composition being provided as a strip for inter-oral administration, method for the... Agent: Leydig Voit & Mayer, Ltd

20070218115 - Preparation for topical application and methods of delivering an active agent to a substrate: A multi-layer dressing and controlled-release composition for topical application to a substrate include an emulsion and an active agent incorporated into the emulsion. The active agent includes a protein. A method of delivering the active agent to the substrate provides the emulsion and incorporates the active agent into the emulsion... Agent: Dinsmore & Shohl LLP

20070218118 - Methods and compositions for treating post- myocardial infarction damage: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix... Agent: Blakely Sokoloff Taylor & Zafman

20070218116 - Compositions and methods for the treatment of tumors and tumor metastases: Compositions and methods for the treatment of tumors and tumor metastases Compositions and methods are provided to treat or prevent growth of tumors and tumor metastases, in particular of the following malignancies: breast cancer, cancer of the ovaries, cervical cancer, colorectal cancer, cancer of the prostate, lung cancer, cancer of... Agent: Harness, Dickey & Pierce, P.L.C

20070218121 - Compounds that inhibit caspase activity for treating glaucoma: Compounds that inhibit caspase activity, particularly those that bind a caspase substrate and protect it, are combined with a vector such as liposomes or an antennapeida peptide to treat glaucoma.... Agent: Fish & Richardson PC

20070218120 - Ph sensitive block copolymer and polymeric micelle using the same: Disclosed is a pH-sensitive block copolymer obtained by copolymerization of: (a) a polyethylene glycol compound (A); and (b) at least one poly(amino acid) compound selected from the group consisting of a poly(β-amino ester) and poly(amido amine) or a copolymer thereof (B). A method for preparing the same block copolymer, and... Agent: Sughrue Mion, PLLC

20070218124 - Polymerizable emulsions for tissue engineering: Provided are biocompatible viscoelastic solid materials derived from polymerization of fluid water-in-oil emulsions, along with methods of their preparation and methods for their use for tissue engineering applications, including for reforming diseased, damaged or degenerated intervertebral discs by acceptably non-invasive means.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20070218123 - Polymersomes and related encapsulating membranes: The present invention provides biocompatible vesicles comprising semi-permeable, thin-walled encapsulating membranes which are formed in an aqueous solution, and which comprise one or more synthetic super-amphiphilic molecules. When at least one super-amphiphile molecule is a block copolymer, the resulting synthetic vesicle is termed a “polymersome.” The synthetic, reactive nature of... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20070218122 - Sirna silencing of influenza virus gene expression: The present invention provides siRNA molecules that target influenza virus gene expression and methods of using such siRNA molecules to silence influenza virus gene expression. The present invention also provides nucleic acid-lipid particles that target influenza virus gene expression comprising an siRNA that silences influenza virus gene expression, a cationic... Agent: Townsend And Townsend And Crew, LLP

20070218119 - Sterol enriched mixed lammelarity amphotericin intercalating liposomes in saline and the process for their preparation: The present invention relates to sterol enriched mixed lamellarity Amphotericin intercalating liposomes in saline for treatment of infections primarily parasitic infection especially those caused by intracellular protozoan parasites. The invention further relates to increasing circulation time of the drug encapsulated in the liposomes in the blood by subjecting liposomal pharmaceuticals... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070218117 - Supra molecular construct for delivery of interferon to a mammal: The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a supra-molecular lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070218125 - Gi track delivery systems: A micro encapsulation material for use with storage unstable, therapeutic and nutritional agents which release the therapeutic and nutritional agents in predetermined locations in the gastro intestinal tract in which the microencapsulation material is formed by combining a food grade treated carbohydrate with a water soluble food grade protein. The... Agent: Foley And Lardner LLP Suite 500

20070218126 - Compositions and methods for reducing inflammation and pain associated with acidosis: Compositions and methods for reducing inflammation and pain associated with acidosis. One embodiment of the composition comprises a plurality of carrier particles, wherein the plurality of carrier particles hold a plurality of alkaline compounds, and wherein the alkaline compounds can be delivered to, and absorbed across, lipid membranes into the... Agent: Speckman Law Group PLLC

20070218127 - Capsules derived from asymmetrical production: A method of making a capsule comprising: -forming one or more first films into a hemi-capsule, -filling the hemi-capsule with one or more capsule contents, -applying one or more second film to said hemi-capsule to form a complete capsule, said one or more second film being flat prior to capsule... Agent: Mcdermott Will & Emery LLP

20070218128 - Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention: It has been found that pharmaceutical compositions comprising water insoluble drugs can be manufactured and formulated in a manner ensuring fast dissolution in gastric fluid. Advantageously, the manufacturing process provides a significantly improved stability, thus resulting in compositions that may have a longer shelf life than conventionally formulated and processed... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070218130 - Bisphosphonate composition and process for the preparation thereof: The present invention is generally directed to pharmaceutical compositions and process for the preparation of same which are suitable for oral administration to a human patient, comprising: a pharmaceutically-acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; a non-reducing sugar diluent; a binder; a disintegrant; and a lubricant, and various other excipients.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070218129 - Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof: The invention relates to an immediate release dispersible and orodispersible solid pharmaceutical composition having the form of particles with a size lower than 710 μm, containing the metformin active ingredient, characterized in that it comprises: a) from 65% to 90% in weight of the metformin active ingredient, optionally under the... Agent: Arent Fox PLLC

20070218131 - Effervescent formulations comprising desmopressin: An effervescent formulation comprising desmopressin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising desmopressin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the desmopressin.... Agent: Nixon Peabody LLP - Patent Group

20070218133 - Sustained release additives for fermentation products: A sustained release delivery system and composition of materials for slowly releasing an additive to a fermentation fluid over a sustained period of time of up to 96 hours is described. The product of the present invention includes a complement of additives and a sustained release mechanism to allow a... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20070218132 - Device and method for identifying and treating vaginal affections: The present invention relates to a pH test glove bearing a reporter substance indicating the possible presence of vaginal affection. such as infections, in particular bacterial vaginosis, or vaginitis. This glove is easy to use, accurate and safe for the woman using it. The present invention also provides packages comprising... Agent: Lucas & Mercanti, LLP

20070218134 - Compositions comprising organic compounds: The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, said composition comprising a core consisting of an inner phase (internal) and an outer phase (external) wherein the outer phase does not comprise a matrix former... Agent: Novartis Corporate Intellectual Property

20070218135 - Sustained release matrix pharmaceutical composition: A sustained release pharmaceutical composition in solid dosage form is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical agents; (b) a first high viscosity release retarding cellulose ether; and (c) a second high viscosity release retarding cellulose ether, wherein the first and second high viscosity... Agent: M. Carmen & Associates, PLLC

20070218136 - New mandelic acid derivatives and their use as thrombin inhibitors: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus,... Agent: Morgan Lewis & Bockius LLP

20070218137 - Sustained release matrix systems for highly soluble drugs: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable... Agent: Davidson, Davidson & Kappel, LLC

20070218138 - Pharmaceutical compositions: Forms and formulations of VX-950 and uses thereof.... Agent: Fish & Richardson PC

20070218141 - Simvastatin compositions: The present invention relates to pharmaceutical compositions comprising simvastatin or pharmaceutically acceptable salts, solvates, enantiomers or mixtures thereof, processes for preparing the same and methods of use and treatment.... Agent: Dr. Reddy's Laboratories, Inc.

20070218139 - High pressure compaction for pharmaceutical formulations: Methods for producing a pharmaceutical preparation of pressure-fused particles including an active pharmaceutical ingredient are disclosed. The methods include the application of a pressure of between 0.1 GPa and 10 GPa to produce a compacted sample. The pressure-fused particles of the invention are useful for parenteral administration, and particularly sustained-release... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070218140 - Slow-release preparations and their method of production: [Problem] To provide pharmaceutical preparations where the dissolution of an amine drug can be effectively controlled. [Resolution Means] Slow-release granules formed by providing a coating layer containing polyvinyl acetate and surfactant on drug-containing particles comprising an amine drug and a water-soluble binder coated onto the surface of a core material;... Agent: Connolly Bove Lodge & Hutz, LLP

20070218142 - Pharmaceutical formulations for the prolonged release of interleukins and their therapeutic applications: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of an interleukin (IL) (and one or more other possible active principles), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a... Agent: Patton Boggs LLP

20070218143 - Topical preparation: A pharmaceutically elegant, rapidly penetrating, therapeutically useful topical combination of thymol, cod liver oil, camphor, peppermint oil and beeswax and the method for the preparation thereof.... Agent: Joseph Koorkin Andonian

20070218144 - Multi-purpose bio-material composition: The present invention relates to a multi-purpose bio-material. One preferred embodiment of the present invention generally comprises: KH2PO4, a metal oxide (i.e. MgO), a calcium containing compound, a sugar and water (or an aqueous solution). Exemplary calcium containing compounds include but are not limited to tri-calcium phosphate, hydroxyapatite, CaSiO3 and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070218145 - Methods and kits for potentiating skin care agents: The present invention provides a treatment method for administering a skin care product to the skin of a subject comprising applying a self heat generation composition into an area of the skin to generate heat locally, wherein the skin care product is administered to the area of the skin before,... Agent: Kenyon & Kenyon LLP

20070218146 - Lipoxygenase and cyclooxygenase inhibition: The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-l (COX-1) and cyclooxygenase-2 (COX-2), using processed Mortinda... Agent: Kirton And Mcconkie

20070218147 - Peroxisome proliferator-activated receptor (ppar) activator, and drugs, supplements, functional foods and food additives using the same: It is intended to provide a peroxisome proliferator-activated receptor (PPAR) activator, which is free from the problem of side effects, can be taken over a long term and has no characteristics taste. β-cryptoxantine is employed as a PPAR activator. β-cryptoxantine, which is contained in a large amount in the pulp... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070218148 - Essential oils inhibit mold on wood: Methods of treating wood lumber to inhibit growth of mold fungi by surface treating the wood lumber with an essential oil being geranium Egyptian, thyme, dill weed or rosemary. Various surface treatments include dipping, spraying, brushing and vapor exposure.... Agent: Janet I. Stockhausen Usda Forest Service

20070218149 - Composition for treating joint or muscle pain: The present invention relates to treatment of joint or muscle pain and, in particular, combinations of ingredients for such treatment. The invention provides a composition, which includes the following components: emu oil, a salicylate analgesic agent, devil's claw, and ginger. The components are present in the composition in an amount... Agent: Hoffmann & Baron, LLP

20070218150 - Active oxygen scavenging agent and moisturizing agent containing wild watermelon extract: It is intended to provide a composition containing wild watermelon extract. More specifically speaking, it is intended to provide an active oxygen scavenging agent containing wild watermelon extract, a method of producing the same and a method of using the same, and a moisturizing agent containing wild watermelon extract, a... Agent: Posz Law Group, PLC

20070218151 - Process for obtention of decoctions of vitis labrusca and vitis vinifera skins: The present invention deal with a process to obtain a decoction from Vitis Labrusca and Vitis skins; process to obtain a hydro-alcoholic and hydro-alcoholic-ethyl acetate obtained from the decoction; pharmaceutical preparations containing the decoction and the before mentioned extracts and therapeutic utilization of the preparations and the prevention and treatment... Agent: Arent Fox PLLC

20070218152 - Process for obtention of decoctions of vitis labrusca and vitis vinifera skins: The present invention deal with a process to obtain a decoction from Vitis Labrusca and Vitis skins; process to obtain a hydro-alcoholic and hydro-alcoholic-ethyl acetate obtained from the decoction; pharmaceutical preparations containing the decoction and the before mentioned extracts and therapeutic utilization of the preparations and the prevention and treatment... Agent: Arent Fox PLLC

20070218153 - Palliative effects of morinda citrifolia oil and juice: A method of preventing and treating various ailments and diseases by utilizing the Cox-2 selective inhibition characteristics of processed Morinda citrifolia.... Agent: Michael F. Krieger Kirton & Mcconkie

20070218154 - New remedy: an all natural remedy for the relief of muscle and joints pain: New Remedy is all natural remedy for the relief of muscle and joint pain. The mode of application has been basically the same since the beginning of time—using your hands to massage a site with or without something to relieve pain. However, this product is new, and made from what... Agent: Mary Erranna Williams

20070218155 - Methods and compositions for treating dyslipidaemia: Disclosed are methods for lowering cholesterol and treating heart disease in an animal employing prenylchalcones or prenylflavonones. Such prenylchalcones or prenylflavonones may be derived from hops (humulus Lupulus L.), or produced synthetically. Representative prenylchalcones or prenylflavonones are: xanthohumol, xanthogalenol, desmethylxanthohumol (2′,4′,6′,4-tetrahydrooxy-3-C-prenylchalcone), 2′,4′,6′,4-tetrahydrooxy-3′-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5′-prenylxanthohumol, tetrahydroxanthohumol, 4′-O-5′-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol,... Agent: Thorpe North & Western, LLP.

20070212324 - Personal care compositions containing quaternary ammonium trihydroxy substituted dipropyl ether: A personal care composition is provided which includes a trihydroxy and quaternary ammonium substituted dipropyl ether. The substituted dipropyl ether functions as a humectant when applied to human skin to moisturize both in high and low relative humidity environments.... Agent: Unilever Intellectual Property Group

20070212297 - Amino methyl imidazoles and related compounds as c5a receptor modulators: Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in... Agent: Neurogen Corporation

20070212298 - Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma: Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNFα, or with temozolomide, TNFα,... Agent: Michael Best & Friedrich, LLP

20070212299 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20070212300 - Delivery of compounds with rehydrated blood cells: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the sane. The blood cells may be red blood cells or blood platelets.... Agent: Myers Bigel Sibley & Sajovec

20070212301 - Monkey immunoglobulin sequences: Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain constant regions derived from cynomolgus monkeys. Chimeric antibodies with cynomolgus monkey constant regions are described.... Agent: Amgen Inc. Law Department

20070212302 - Preparation and use of a stable formulation of allosteric effector compounds: A pharmaceutical composition of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salts suitable for parenteral administration includes an aqueous formulation of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salt and a buffer to maintain the pH from about 6 to about 11. The composition in accordance with the invention reduces the amount... Agent: Swanson & Bratschun, L.L.C.

20070212305 - Optical imaging contrast agents for imaging lung cancer: The invention provides contrast agents for optical imaging of lung cancer in patients. The contrast agents may be used in diagnosis of lung cancer, for follow up of progress in disease development, for follow up of treatment of lung cancer and for surgical guidance. Further, the invention provides methods for... Agent: Ge Healthcare, Inc.

20070212303 - Compositions and methods for enhancing contrast in imaging: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20070212304 - Method to assess surfactant adsorption on skin: A convenient to use test method for comparing the relative affinity of surfactants for the skin employs a solid or semisolid matrix for associating a dye or pigment with the skin. The dye or pigment has an affinity to either the skin or a surfactant adsorbed on the skin during... Agent: Unilever Intellectual Property Group

20070212306 - Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides: Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results wherein the composition is free of a stabilizer that is a protein or a polypeptide. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more... Agent: Nastech Pharmaceutical Company Inc

20070212307 - Pharmaceutical compositions comprising an opioid receptor antagonist and methods of using same: The present invention features compositions for intranasal administration comprising an opioid receptor antagonist. The invention also features methods of using such compositions in the treatment of various diseases and disorders, such as the treatment of alcoholism. In certain embodiments, the opioid receptor antagonist is naltrexone or a pharmaceutically acceptable salt... Agent: Goodwin Procter LLP Patent Administrator

20070212308 - Methods and compositions for treating asthma in human and non human primates: The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.... Agent: Dla Piper US LLP

20070212309 - Hair moisturizing process: A method of moisturizing hair comprising the steps of cooling a hair care product and applying the cooled hair care product to the hair. The hair care product may be cooled before it is applied to the hair and/or as it is applied to the hair. The hair care product... Agent: Advantia Law Group

20070212310 - Antimicrobial smoke flavor for oral microflora control: The presently disclosed subject matter provides compositions and methods for inhibiting the growth of oral microbes in a subject. Particularly, the methods include applying an oral composition comprising an oral care delivery agent and an antimicrobial agent comprising an effective amount of a low flavor antimicrobial liquid smoke derivative to... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070212311 - Recombinant alkalinizing bacteria: Compositions and methods utilizing recombinant alkalinizing bacteria which include isolated nucleic acid constructs. The genetically engineered cells express at least one alkali producing enzyme, such as a urease, an arginine deiminase or an agmatine deiminase, which produce the alkali ammonia. When used in the mouth of a subject, the presence... Agent: Akerman Senterfitt

20070212312 - Metal oxide composite oxide and cosmetic including the same: The present invention relates to metal oxide complex powder obtained by polymerizing a polymerizable and unsaturated group-containing monomer via a polymerization initiation group introduced onto the surface of at least one metal oxide selected from zinc oxide, titanium oxide and cerium oxide and cosmetics containing the metal oxide complex power.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070212313 - Anhydrous antiperspirant composition: An antiperspirant composing calcium sulfate hemihydrate in an anhydrous state or in an anhydrous composition and method of treating hyperhidrosis.... Agent: Schnader Harrison Segal & Lewis, LLP

20070212314 - Silicone adhesive formulation containing an antiperspirant: This invention relates to a method of enhancing the adhesion of a silicone containing adhesive formulation. The method comprises mixing 1 to 99.9 wt. % of a silicone-containing adhesive formulation and 0.1 to 50 wt. % antiperspirant compound to form a composition. The composition is then applied onto a surface... Agent: Dow Corning Corporation Co1232

20070212317 - Hydrocarbon complex mascara: Disclosed are mascara compositions that contain a thermoplastic elastomer, a tackifier, a volatile solvent, and a non-polar non-volatile solvent, and methods of making and using the compositions.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070212318 - Photoactivatable diazirine-active agent compounds, compositions comprising them and uses thereof: Disclosed herein are a cosmetic composition comprising at least one diazirine active-agent compound comprising a diazirine covalently bonded to a cosmetic active agent, said at least one diazirine-active agent compound and the uses of the composition or of the compound, as well as cosmetic treatment processes using the composition or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070212319 - Low-odor dimethicone copolyol sulfosuccinate surfactant compositions: Dimethicone copolyol sulfosuccinate surfactant compounds having low-odor characteristics are disclosed. The low-odor dimethicone copolyol sulfosuccinate is substantially free from propionaldehyde and acid-releasable precursors of propionaldehyde, thereby substantially eliminating the cosmetically undesirable odor characteristic of conventional dimethicone copolyol sulfosuccinate surfactants. The low-odor dimethicone copolyol sulfosuccinates are suitable for use as surfactants... Agent: Olson & Hierl, Ltd.

20070212320 - Care system constituted of pvp and acrylate polymers: The invention relates to cosmetic and dermatological detergent preparations for cleansing the skin and/or for cleaning hair and scalp. The inventive preparations comprise (a) an effective amount of one or more anionic detergents, (b) an effective amount of one or more amphoteric detergents, (c) an effective amount of one or... Agent: Greenblum & Bernstein, P.L.C

20070212321 - Aqueous dispersions of water-soluble and/or water-swellable anionic polymers, method for their production and use thereof: Aqueous dispersions of water-soluble and/or water-swellable anionic polymers which are obtainable by free radical polymerization of ethylenically unsaturated, anionic monomers in an aqueous medium in the presence of at leas one stabilizer, the polymerization being carried out in the presence of at least one water-soluble polymer of the groups consisting... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070212322 - Cosmetic composition comprising a block copolymer: The present invention relates to a cosmetic composition comprising at least one diblock copolymer, as well as to the use of the said diblock copolymer as a modifier of properties of cosmetic compositions, more preferably of compositions for the skin and/or the hair. The diblock copolymer comprises two blocks, block... Agent: Rhodia Inc.-legal Department

20070212323 - Hydrophilic structured predominantly soap-based bar compositions comprising individually coated flat platy particles, each having surface deposition chemistry mechanism: The invention relates to fatty acid soap bar compositions comprising flat platy particles wherein the particles individually have deposition system (i.e., cationic polymers and anionic surfactant) on them.... Agent: Unilever Intellectual Property Group

20070212316 - Mascara composition with self-emulsifying waxes and latex polymers: Disclosed are mascara compositions containing a latex polymer, a self-emulsifying wax in an amount of at least 15% by weight of the composition, and water, and methods of making and using the compositions.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070212315 - Mascara compositions: The invention relates to compositions for eyelashes such as mascaras, topcoats and basecoats containing (a) at least one fatty alkoxylated dimeric compound; and (b) at least one polymeric compound selected from the group consisting of a polyorganosiloxane-containing polymer, a non-silicone polyamide copolymer, a hydrocarbon resin, a styrene-containing copolymer, and mixtures... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070212325 - Insulin resistance-improving agent: A medicament comprising a pharmaceutically acceptable anion exchange resin as an active ingredient is provided which exhibits an insulin resistance-improving action regardless of volume of meal or glucose absorption from the gastrointestinal tract.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070212326 - Polyquaternary organosilicon compounds-containing composition: Polymers containing repeating organopolysiloxane blocks and including quaternary ammonium groups in the polymer chain exhibit good biocidal properties, while also exhibiting good washfastness, hydrophilicity, and softness.... Agent: Brooks Kushman P.C.

20070212327 - Allergen depressant and depression method: The invention provides a means capable of effectively inactivating and removing allergen or a precursor thereof. The invention relates to an allergen-reducing agent containing water and a water-soluble polymer compound having units having hydroxy or carboxy groups wherein at least a part of hydrogen atoms of the hydroxy or carboxy... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070212328 - Immunogenic compositions: The invention relates to a combination therapy that finds utility in the treatment or prophylaxis of infectious diseases, cancers, autoimmune diseases and related conditions. In particular, the combination therapy comprises the administration of a TH-1 cytokine, in particular IL-18, and an immunogenic composition, in particular a vaccine, comprising an antigen... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070212329 - Vaccine compositions comprising an interleukin 18 and saponin adjuvant system: This invention relates to a combination therapy that finds utility in the treatment or prophylaxis of infectious diseases, cancers, autoimmune diseases and related conditions. In particular, the combination therapy comprises the administration of a TH-1 cytokine, in particular, IL-18, and an immunogenic composition, in particular, a vaccine, comprising an antigen... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070212330 - Nucleic acid molecules as herpanase potent inhibitors, compositions and methods of use thereof: Disclosed herein are ribonucleic acid molecules, specifically ribozymes and siRNAs, whose sequence is at least partially complementary to heparanase mRNA. Said molecules may thus be used for the specific inhibition of heparanase, and as therapeutics for pathologic conditions associated with heparanase expression, like for example tumor formation, progression and metastasis,... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070212334 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Dla Piper US LLP Attn: Patent Group

20070212331 - Methods and compositions for selectively killing cells: The inventors have discovered that increased levels of intracellular zinc leads to cell death by apoptosis and necrosis. Surprisingly, p53 minus cells under cell death when treated with zinc. Thus, the invention is directed to zinc compositions useful in the targeted delivery of zinc compounds to cancer cells, to kill... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20070212333 - Methods and compositions for the treatment of dystonia: The present invention relates to methods and compositions for the treatment of dystonia in a mammal. More particularly the methods of the invention involves decreasing the expression of wild-type Dyt1 in the Purkinje cells of mammals exhibiting symptoms of dystonia in order to treat the dystonia.... Agent: Marshall, Gerstein & Borun LLP

20070212332 - Methods for accelerating bone repair: Vectors, such as retroviral vectors and transposon-based nonviral vectors, are disclosed herein that can be used to target transgene expression to the proliferating periosteal cells and cells in the marrow space after bone fracture. In one embodiment, these vectors include a human Cox-2 gene that is modified to improve mRNA... Agent: Klarquist Sparkman, LLP

20070212338 - Hybrid cells: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiated, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of... Agent: Foley And Lardner LLP Suite 500

20070212337 - Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders: The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms that are specifically targeted to neoplastic cells, including tumor cells. Methods of... Agent: Dla Piper US LLP

20070212336 - Methods for harvesting and storing autologous stem cells including blood derived hematopoietic stem cells and adipose derived mesenchymal stem cells: A method of collecting and storing stem cells from a patient is disclosed. The method includes the steps of obtaining a micro quantity of stem cells from the patient, cryogenically preserving the micro quantity of stem cells for a period of time, and reintroducing into the patient at least a... Agent: Donald Bollella

20070212335 - Treatment of alopecia by micropore delivery of stem cells: A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles.... Agent: Reliant / Fenwick C/o Fenwick & West, LLP

20070212339 - Use of at least one effector of glutathione metabolism together with alpha-lipoic acid for the treatment of chronically obstructive lung diseases: The present invention relates to the use of at least one effector of glutathione metabolism together with α-lipoic acid, its salts and/or its pro-drugs for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20070212340 - Use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses: A method for the prophylactic and therapeutic treatment of bacterial infections of the skin is disclosed which comprises the treatment of an individual with an effective amount of a native or altered version of a lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria. The... Agent: Jonathan E. Grant

20070212341 - Method for preparing active kinases containing ph domains: The invention relates to a method for preparing active kinases which, in native form, contain a pH domain.... Agent: Nath & Associates PLLC

20070212343 - Compositions for treatment of ear infections: Topical otic pharmaceutical compositions comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof and a proteolytic enzyme. The compositions facilitate trans-tympanic delivery of a therapeutic level of the moxifloxacin.... Agent: Alcon

20070212344 - Pharmaceutical preparation with rna as hemostasis cofactor: Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described. They are in particular advantageously employed together with an activator for hemostatic processes such as factor VII-activating protease (FSAP).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070212342 - Protease compositions for the treatment of damaged tissue: The invention is directed to compositions containing one or more proteases that are beneficial in the treatment of damaged tissue, wounds and inflammation. The compositions of the invention modulate the levels and activity of proteins that are present at wound and inflammation sites and promote the repair of damaged tissue.... Agent: Morgan Lewis & Bockius LLP

20070212349 - Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody... Agent: Leydig, Voit & Mayer, Ltd.

20070212348 - Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation: Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind sphingolipids or sphingolipid metabolites. In one embodiment the agent is an... Agent: Biotechnology Law Group C/o Portfolioip

20070212347 - Compositions and methods for treating polycystic kidney disease gene: The present invention provides an isolated antibody or fragment thereof that binds to an epitope present in the transmembrane domain of polycystin and specifically recognizes a polycystin-related polypeptide having an apparent molecular weight in the range of about 600 to about 800 kD. Polynucleotides, polypeptides, gene delivery vehicles and host... Agent: Genzyme Corporation Legal Department

20070212346 - Highly concentrated stabilized igm solution: The present inventors discovered that stable and highly concentrated IgM solutions can be prepared by using, as an additive, a compound comprising a polyvalent cationic ion, such as magnesium chloride or arginine hydrochloride, to suppress IgM aggregation in solutions.... Agent: Fish & Richardson PC

20070212345 - Methods and compositions for the prevention and treatment of gentiourinary disorders including pre-term labor and leiomyomas: The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases.... Agent: Fulbright & Jaworski L.L.P.

20070212350 - Rs7 antibodies: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins... Agent: Faegre & Benson LLP Patent Docketing

20070212351 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Sagres Discovery Inc. Intellectual Property - R440

20070212352 - Methods and compositions for the treatment of polycystic diseases: This invention provides compositions and methods to diagnose and treat polycystic disorders by inhibiting the biological activity of a gene now correlated with appearance of this disorder. By way of illustrative only, the Tissue Growth Factor-alpha (TGF-α) gene is an example of such a gene. Also provided by this invention... Agent: Genzyme Corporation Legal Department

20070212353 - Novel therapeutic target and diagnostic marker for asthma and related conditions: CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070212357 - Anti-ngf antibodies and methods using same: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.... Agent: Pfizer Inc

20070212356 - Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.... Agent: Genentech, Inc.

20070212355 - Glp-2 mimetibodies, polypeptides, compositions, methods and uses: Mammalian GLP-2 mimetibodies, polypeptides and nucleic acids are disclosed. Methods of utilizing the mimetibodies and polypeptides to treat GLP-2 related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070212354 - Use of vegf antagonists for the treatment of malignant gliomas: Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of... Agent: Regeneron Pharmaceuticals, Inc

20070212358 - Compositions and methods for effecting controlled posterior vitreous detachment: A composition comprises plasmin or an enzymatically equivalent derivative thereof and an inhibitor of at least an enzyme that is activatable, directly or indirectly, by plasmin or one of its enzymatically equivalent derivatives. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent,... Agent: Bausch & Lomb Incorporated

20070212359 - Cancer diagnosis and treatment of cancer using anti-robo 1 antibody: A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that... Agent: Davidson, Davidson & Kappel, LLC

20070212360 - Modulation of mitochondrial oxygen consumption for therapeutic purposes: The HIF-1 transcription factor drives gene expression changes in hypoxia. While HIF-1 stimulates glycolysis, it also actively represses mitochondrial function and oxygen consumption by inducing pyruvate dehydrogenase kinase 1 (PDK1). PDK1 phosphorylates and inhibits pyruvate dehydrogenase from converting pyruvate to acetyl-CoA to fuel the mitochondrial TCA cycle. This causes a... Agent: Bozicevic, Field & Francis LLP

20070212361 - Monoclonal antibodies to human high molecular weight-melanoma associated antigen: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.... Agent: Wyeth C/o Darby & Darby, P.C.

20070212362 - Use of il-17 antibody for the treatment of cartilage damaged by osteoarthritis: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilagenous disorders, including degenerative cartilagenous disorders such as arthritis, comprising the administration of IL-17 and/or LIF antagonists (e.g., anti-IL-17 and anti-LIF antibodies). Optionally, the administration may be in combination with a... Agent: Genentech, Inc.

20070212363 - Immunoglobulins with potent and broad antiviral activity: A (poly)peptide-Fc fusion molecule, such as an scFv-Fc fusion molecule comprising an scFv fragment and an Fc region from an antibody, related nucleic acids, vectors, and host cells, and a method of inhibiting a viral infection in a mammal, which method comprises administering to a mammal in need thereof the... Agent: Leydig, Voit & Mayer, Ltd.

20070212364 - Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.... Agent: Foley And Lardner LLP Suite 500

20070212369 - Colon specific genes and proteins: Human colon specific gene polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for colon cancer and as an agent to determine if colon cancer has... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070212367 - Novel immunologically active peptide fragments of a proline-rich polypeptide isolated from colostral mammalian fluids for treatment of viral and non-viral diseases or diseased conditions: Present invention relates to an immunologically active nonapeptide fragments of a proline-rich polypeptide isolated from mammalian colostral fluids for treatment of viral and non-viral diseases or diseased conditions, a method and a system for processing mammalian colostral fluids for isolating target peptides and proteins, a pharmaceutical formulation containing such peptides... Agent: Dr. Andrew Maurice Keech

20070212365 - Novel plexin polypeptide, dna encoding the same and use thereof: The object of the invention is to provide novel DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide, or an antibody against the polypeptide, which is useful for development and screening of prophylactic, therapeutic and diagnostic drug for angiogenesis and conservation... Agent: Birch Stewart Kolasch & Birch

20070212368 - Proteins: The present invention provides methods and compositions for screening, diagnosis and prognosis of breast cancer, for monitoring the effectiveness of breast cancer treatment, and for drug development.... Agent: Klauber & Jackson

20070212366 - Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases: The invention relates to the use of inhibitors of the multidrug resistance protein 4 (MRP4) in thrombocytes for the treatment and/or prophylaxis of cardiovascular diseases.... Agent: Marshall, Gerstein & Borun LLP

20070212370 - Soluble cd83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving t cells: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies... Agent: Norris, Mclaughlin & Marcus, Pa

20070212371 - Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants: Processes are described for preparing 42-pegylated rapamycins including reacting a rapamycin with an acylating agent in the presence of a lipase to form an acylated rapamycin and reacting the acylated rapamycin with a methoxy poly(ethylene glycol) derivative in the presence of a base. Also described are processes for preparing 32-pegylated... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070212372 - Methods for the treatment and prophylaxis of demeyelinating disease: The present invention relates to a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition and even more particularly an encephalomyelopathic condition. The present invention... Agent: Edward W. Grolz Scully, Scott, Murphy & Presser

20070212373 - Lawsonia intracellularis 26 kd subunit vaccine: e

20070212375 - Process for producing in yeast empty viral capsids consisting of proteins derived from pvp2 of the infectious bursal disease virus (ibdv): The empty capsids of the infectious bursal disease virus (IBDV) are formed by the assembly of proteins derived from the pVP2 protein of IBDV, with a different size and with an application in producing vaccines and in preparing gene therapy vectors.... Agent: Klarquist Sparkman, LLP

20070212374 - Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus l1 proteins, and uses thereof: Novel acetone- or alcohol-fixed viral capsid proteins, bacteria-containing, and papillomavirus L1-GST fusion proteins are described. These proteins are useful in vaccine preparation and as diagnostics.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070212376 - Method of treating and preventing infectious diseases: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070212377 - Recombinant herpesvirus and uses thereof: A recombinant herpesvirus (excluding infectious laryngotracheitis virus) having a DNA that encodes a polypeptide comprising 429 amino acids at the amino terminal end of a protein encoded by the gB gene of infectious laryngotracheitis virus or a polypeptide in which one or a plurality of amino acids have been deleted,... Agent: Kratz, Quintos & Hanson, LLP

20070212378 - Methods and compositions for mycoplasma pneumoniae exotoxins: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided... Agent: Myers Bigel Sibley & Sajovec

20070212379 - Preparation of vaccines using photosensitizers and light: Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but... Agent: Gambro, Inc Patent Department

20070212380 - Conjugated fatty acid based emulsion and methods for preparing and using same: Stable emulsions comprising as a base one or more diene conjugated fatty acids. Amino acids and other macromolecules can be used to stabilize the emulsion. The emulsion is also useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the macromolecules. Plant oil... Agent: Middleton & Reutlinger

20070212381 - Modulating agents for antimicrobial coatings: An exemplary medical device for subcutaneous disposal at least partially within a patient is disclosed, comprising an antimicrobial material comprising at least one metal and an agent that inhibits diffusion of the at least one metal from the antimicrobial material. The antimicrobial material comprises a coating formed over at least... Agent: Stoel Rives LLP - Slc

20070212382 - Composition for combating ectoparasites and their ova: Compositions for combating ectoparasites, and particularly head lice and their nits comprise a low viscosity linear polysiloxane combined with a higher viscosity linear polysiloxane and at least one spreading agent. The low viscosity linear polysiloxane has a viscosity of less than 10 cSt and is present in a weight percentage... Agent: Schweitzer Cornman Gross & Bondell LLP

20070212383 - Juvenile hormone compositions and methods for making same: The present invention relates to hormone coating layers having desirable hormone delivery characteristics and product lifetime. In one embodiment, the invention is a hormone composition including a substrate having an external surface, and a coating layer disposed on the external surface. The coating layer preferably includes a polymer web, and... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070212386 - Coatings for implantable medical devices: An implantable medical device comprising an expandable balloon having an outer surface, a polymer coated on at least a portion of the outer surface of the balloon, and a pharmaceutically active agent dispersed within the polymer.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070212387 - Coatings for implantable medical devices: A composition comprising at least one polymer covalently bonded to heparin, and at least one pharmaceutically active agent other than heparin dispersed within the at least one polymer.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070212388 - Compositions comprising porous articles and uses in implantable medical devices: A composition comprising a first polymer having pores, nanoparticles dispersed within the pores of the first polymer, the nanoparticles comprising a second polymer and at least one pharmaceutically active agent dispersed in the second polymer, and heparin covalently bonded to at least one of the first and second polymer.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070212384 - Altering animal waste compositiion: A delivery device for altering the composition of animal waste, characterized in that the delivery device is adapted to deliver to an animal one or more treatment substances that can directly or indirectly affect the conversion of nitrogen containing compounds to animal waste, once the waste is excreted from the... Agent: Knobbe Martens Olson & Bear LLP

20070212385 - Fluidic tissue augmentation compositions and methods: Compositions and method for augmenting tissue after delivery to localized area. The compositions include a hydrogel and a dermal filler. The hydrogel can polymerize and/or crosslink upon a first trigger event. The dermal filler can also optionally crosslink upon a second trigger event.... Agent: Wilson Sonsini Goodrich & Rosati

20070212393 - Compositions and coatings for implantable medical devices: An implantable medical device, comprising a polymer coated on at least a portion of the medical device, and a pharmaceutically active agent covalently bonded to the polymer.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070212392 - Chemoprevention of endometrial cancer: The present invention is directed to intrauterine devices that release progestins or an inflammatory cytokine after placement. These devices can be used to reduce the risk of a woman developing endometrial cancer. The invention is also directed to therapeutic methods in which a sample of uterine cells obtained from a... Agent: Law Office Of Michael A. Sanzo, LLC

20070212390 - Protease-resistant forms of vegf-d, method of making and method of use: The present invention provides modified VEGF-D polypeptide variants that are resistant to serine protease processing and methods of making and using the same, as well pharmaceutical compositions comprising the peptide or a polynucleotide encoding the same. The VEGF-D variants comprise a VEGF homology domain, and at least one of (1)... Agent: David A. Gass Marshall Gerstein & Borun, LLP

20070212391 - Stabilised prostaglandin composition: A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel. The polyurethane is either linear or cross-linked.... Agent: Dla Piper US LLP Attn: Patent Group

20070212394 - Taxane coatings for implantable medical devices: This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired... Agent: Brinks Hofer Gilson & Lione/indy/cook

20070212389 - Use of a hydrogel for the culture of chondrocytes: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.... Agent: Stites & Harbison PLLC

20070212396 - Autologous cells on a support matrix for tissue repair: The present invention relates to a method for the effective treatment of tissue defects and for tissue regeneration. The method includes seeding autologous cells on a support matrix and implanting the cell-seeded support matrix into a site of transplantation. The present invention also relates to various tissue repair structures that... Agent: Morgan, Lewis & Bockius LLP

20070212395 - Ocular therapy using sirtuin-activating agents: Ophthalmically therapeutic compositions, such as polymeric drug delivery systems, include a therapeutic component that includes a sirtuin-activating agent, such as resveratrol, which, upon delivery to the posterior segment of a mammalian eye, treats ocular conditions. Methods of making and using the present compositions are also described.... Agent: Stephen Donovan Allergan, Inc.

20070212397 - Pharmaceutical delivery device and method for providing ocular treatment: Disclosed herein is a novel pharmaceutical delivery device that provides controlled, sustained local delivery of a therapeutic agent of interest to a target tissue of interest, for example, the vitreous tissue of the eye, over an extended period of time.... Agent: Smith Patent Consulting Consulting, LLC

20070212399 - Pyroligneous liquor sheet: The present invention relates to a pyroligneous liquor sheet containing a pyroligneous powder, and more particularly to a pyroligneous liquor sheet having an excellent effect of removing waste matters by means of a contact surface with a human body. The pyroligneous liquor sheet according to the present invention provides a... Agent: Jones Day

20070212400 - Modified cyclodextrin film or fiber, and method for producing the same: It is possible to produce a pigment-modified cyclodextrin film or fiber expected to be versatile in medicines, foods and pesticides such as packing films like wafer (for example, films to wrap food or drugs, and packages whose colors change when contained food begins to leak). It is comprised by p-methyl... Agent: Birch Stewart Kolasch & Birch

20070212398 - Powdered wipe: A dry wipe to remove sand from a skin surface is provided. The wipe includes a substrate having a hydrophilic powder disposed thereon. The dry wipe is manufactured by the process of providing a wet substrate; applying a hydrophilic powder to at least one side of the wet substrate; and... Agent: Ratnerprestia

20070212401 - Single-use cosmetic article comprising a support impregnated with a lotion containing oxyethylenated sorbitan monolaurate comprising 4 oe: The present disclosure relates to a single-use cosmetic article comprising at least one water-insoluble support impregnated with a lotion. The impregnating lotion comprises water, at least 1% by weight of at least one cosmetically acceptable alcohol and/or at least one cosmetically acceptable polyol, and at least 0.05% by weight of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070212402 - Patch: A patch device adapted for use in the transdermal administration to a patient of a composition including, or consisting of, a selected irritating substance, preferably dimethylformamide or DMF, the patch consisting of a layered construct adapted to be adhered to the skin of a patient and defining a depot cavity... Agent: Hahn And Moodley, LLP

20070212405 - Dispersion for pulmonary delivery of a bioactive agent: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated,... Agent: Nektar Therapeutics

20070212406 - Homeopathic drug composition and methods of use thereof: The present invention comprises homeopathic preparations of compounds, methods for using such preparations and delivery systems for the treatment of disease symptoms through the administration of these homeopathic compositions.... Agent: Bryan Cave LLP

20070212404 - Liposome and method of preparing the same: Provided are a liposome formed by self-assembling a cucurbituril derivative and a method of preparing the liposome.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070212403 - Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same: The present invention is based on the use of electrical surface charge as a docking tool to bring charged lipid assemblies in the vicinity of a diseased, e.g. inflamed epithelium of the mucosa, or alternatively, to a normal epithelium, for executing a desired medical procedure. Thus, the present invention provides... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070212407 - Oral composition a first composition (a) and a second composition (b) as a combination product for separate or consecutive administration in the cosmetic treatment of the human body: The present invention relates to a composition suitable for oral delivery and including a first composition (a) containing a green tea extract and vitamin C, and optionally at least one metal compound selected from zinc, chromium and mixtures thereof, and a second composition (b) containing at least one metal compound... Agent: R Blake Johnston Dla Piper Rudnick Gray Cary Us

20070212408 - Stable pharmaceutical composition containing benzimidazole derivatives and method of manufacturing the same: The present invention relates to an inclusion complex containing a benzimidazole derivative with excellent storage stability and a method of its preparation. In particular, the present invention relates to an inclusion complex containing a benzimidazole derivative with improved storage stability and a method of its preparation, where an inclusion complex... Agent: Ronald R Santucci Frommer Lawrence Haug

20070212409 - Stable pharmaceutical compositions for 2-aza-bicyclo [3.30]-octane-3-carboxylic acid derivatives: A stable composition of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative and a method for its preparation are described. The stable composition includes an intimate admixture of the derivative and a stabilizing effective amount of a lubricant. The stable composition further includes an external excipient. A method of preparing the stable composition includes... Agent: Kenyon & Kenyon LLP

20070212411 - Coating capsules with active pharmaceutical ingredients: Pharmaceutical compositions in unit dose form comprising capsules containing one or more first active pharmaceutical ingredient in a pharmaceutically acceptable vehicle, coated with one or more second active pharmaceutical ingredients, wherein the unit dose form is a pharmaceutical grade finished dosage form, and methods of making and using the same.... Agent: Arent Fox PLLC

20070212410 - Compositions and methods for delivery of amino-functional drugs: Described are flexible, finite systems for the transdermal administration of scopolamine, comprising: (a) a polymer matrix comprising a polymer blend comprising (i) a non-functional acrylic-based polymer constituting at least about 60% by weight of the dry weight of the polymer matrix, and (ii) an amine-resistant capped silicone polymer constituting not... Agent: Foley And Lardner LLP Suite 500

20070212412 - Stable solid formulation of sertindole: The present invention relates to a pharmaceutical composition comprising sertindole and a protective agent absorbing radiation with a wavelenght below 400 nm. The present invention also relates to the use of sertindole for the preparation of a pharmaceutical composition comprising sertindole and a coating layer compsrising said protective agent, such... Agent: Darby & Darby P.C.

20070212416 - Controlled release matrix pharmaceutical dosage formulation: The invention proves a novel compressed tablet of a pharmaceutical compound and a method of making a tablet of a pharmaceutical compound which are based on uncoated pellets containing a pharmaceutical compound that are dispersed in a matrix which comprises said pellets and a swellable polymer which is compressed into... Agent: Hedman & Costigan P.C.

20070212414 - Ethanol-resistant sustained release formulations: The invention provides formulations that resist dose dumping in the presence of ethanol and methods of use thereof. The formulations can be used to prevent dose dumping, to increase safety of drugs, and to reduce abuse of drugs prone to such abuse. The formulations comprise at least one drug and... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070212413 - Sustained-release oral molsidomine composition for treating atherosclerosis: The present invention, which is applicable in the pharmaceutical industry, relates to the use of molsidomine or one of its pharmaceutically acceptable salts, especially in the form of a sustained-release solid oral composition effective over 24 hours, for the manufacture of a drug for preventing or reducing the development of... Agent: Dennison, Schultz & Macdonald

20070212415 - Sustained-release tablet containing doxazosin mesylate: The present invention relates to a sustained-release tablet containing doxazosin mesylate, and more particularly to a sustained-release tablet of which drug release rate maintains constant for 8 hours and longer.... Agent: Sughrue Mion, PLLC

20070212417 - Compressible resilient granules and formulations prepared therefrom: Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %; a sugar alcohol in an amount of about 15 wt % to... Agent: Thorpe North & Western, LLP.

20070212418 - Microparticles comprising somatostatin analogues: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.... Agent: Novartis Corporate Intellectual Property

20070212419 - Synthesis of biocompatible nanocomposite hydrogels as a local drug delivery system: Nanocomposite biocompatible hydrogels (NCHGs) may be synthesised as model systems for in situ cured local drug delivery devices for treatment of inter alia periodontal infections. The composite includes the following components: nanoparticles (NPs), a matrix gel, and chlorhexidine (CHX) or other antibacterial drug. The NPs were obtained by free radical... Agent: Thomas A. O'rourke Bodner & O'rourke, LLP

20070212420 - Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives: An improved pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users. The pharmaceutical formulation comprises at least a polyanionic material and at least a zinc-based compound.... Agent: Bausch & Lomb Incorporated

20070212421 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070212422 - Dry powder for inhalation: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070212423 - Stem cells that transform to beating cardiomyocytes: Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are... Agent: Klarquist Sparkman, LLP

20070212424 - Method of disinfecting food and food preparation areas: Hydrogen peroxide is stabilized by the addition of tri-potassium phosphate at a pH above 9.5. This enhanced product is environmentally friendly and can be used in a variety of odor and disinfection applications without hazard to people, plants and things. Such applications include food and food preparation areas.... Agent: Benasutti, P.A.

20070212425 - Cidal formulations and methods of use: Formulated Cidal compositions containing a metal compound, an inert carrier for the metal compound and, a detergent, wherein the metal and the detergent are present at low concentrations and methods of using Cidal compositions in aqueous environments.... Agent: MckellarIPLaw, PLLC

20070212426 - Composition and method of retarding viral activity and reducing viral replication: A composition comprising of polyphenols, an ascorbic compound, lysine, and proline, have been found to retard viral activity. As such, methods of treating viral infection, and methods of retarding viral activity are provided herein.... Agent: Ali Kamarei Esq

20070212427 - Hormone replacement formulation: The basic formulation comprises a combination of three estrogens, 2-hydroxyestrone, 17-beta-estradiol and estriol, and a metabolite of an estrogen, 2-methoxyestradiol, in specified amounts. Amounts of folic acid, DHEA, testosterone, Vitamin B6, Di-Indolyl Methane, melatonin and progesterone, as well as selenium and cobalt can be added in specific amounts to the... Agent: Jensen + Puntigam, P.s.

20070212428 - Methods and compositions for treating mood disorder: The invention relates to compositions and methods for treating mood spectrum disorder. The compositions relate to novel combinations and formulations of pharmaceutical compounds for treatment of mood spectrum disorders. The methods provide for use of the compounds provided herein for the treatment of mood spectrum disorders in addition to the... Agent: Bingham Mccutchen LLP

20070212429 - Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis: A composition and method for promoting weight loss through the mutual and simultaneously to promotion lipolysis, the expenditure of energy stored in the body as fat, the inhibition of lipolysis as well as affording the body of an individual protection from reactive oxygen species resulting from the β-oxidation of fats.... Agent: Kenyon & Kenyon LLP

20070212430 - Method for weight reduction: A composition for reducing the weight of a human. The composition is provided in the form of a capsule comprising an effective amount of capsaicin and/or analogs thereof, L-tyrosine, supplemental caffeine and/or and analogs thereof, green tea extract containing catechin and caffeine, and embodiments which include calcium. The invention is... Agent: Gordon & Rees LLP

20070212431 - Cream for treatment of skin injured by the sun: This invention relates to a cream of the kind described in the preamble of claim 1 for topical treatment of visibly photodamaged skin caused by processes involving the influence of free radicals and where the cream also affects the energy production of the cells, wherein the active ingredients of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070212432 - Herbal composition: The invention relates to a herbal composition comprising extracts from Thuja, Bupleurum, Echinacea, Calendula, Licorice and Hypercum; formulations containing the herbal composition; and use of the herbal composition for alleviating, treating and/or preventing sypmtoms associated with or caused by viral infections... Agent: Needle & Rosenberg, P.C.

20070212433 - Nutritional formulations and associated methods: Nutritional formulations and methods for imparting positive health benefits to a subject are disclosed and described. In particular, methods and nutritional formulations for providing increased absorption of antioxidants are taught. In some aspects, the nutritional formulation can include Gac fruit extract in combination with at least one other antioxidant. Such... Agent: Thorpe North & Western, LLP.

20070212434 - Compositions and methods for human use containing fulvic acid: The present invention provides compositions comprising fulvic acid. The present invention further provides methods and compositions for promoting hair growth involving the use of fulvic acid.... Agent: Trask Britt

20070207087 - Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).... Agent: Volpe And Koenig, P.C.

20070207101 - Cosmetic compositions comprising sub-micron boron nitride particles: A cosmetic composition for use on hair, skin or nails, containing a safe and effective amount of boron nitride powder has been found which improves the appearance of skin by blurring lines and wrinkles while at the same time providing coverage of age spots, blemishes and other discolorations.... Agent: Momentive Performance Materials Inc.-quartz C/o Dilworth & Barrese, LLP

20070207100 - Method for hair loss disguise: The invention is directed to a process for disguising hair loss by selecting a cosmetic pigmentation to match the color of existing hair; disbursing the cosmetic pigmentation onto the scalp epidermis in the thinning hair area; and blending the cosmetic pigmentation to uniformly cover the scalp epidermis in the thinning... Agent: Black Lowe & Graham, PLLC

20070207103 - Lipophilic personal care composition: The present invention is directed to a water-in-oil emulsion composition comprising: a lipophilic personal care composition comprising by weight: (a) from about 1% to about 30% of a polyglycerin fatty acid ester having a polyglycerin of 2-20 units and at least one branched fatty acid residue of 8 to 22... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070207104 - Antimicrobial esters: and wherein x+y, x+y+z or w+x+y+z, or combinations thereof, has an average value ranging from about 6 to about 100; R is a hydrocarbon comprising from about 3 to about 19 carbons; n is an integer ranging from about 2 to about 4 or combinations thereof; m is an integer... Agent: Mitchell P. Novick, Esq. Law Offices Of Mitchell P. Novick

20070207107 - Silicone based emulsions for topical drug delivery: A water-in-oil emulsion is provided in which the lipophilic phase of the emulsion contains a silicone fluid and an emulsifier, a hydrophilic phase, and a pharmaceutically active compound. The active pharmaceutical ingredient is dissolved or dispersed in the emulsion and is partitioned in the emulsion so that all or a... Agent: Howard Eisenberg, Esq.

20070207112 - Anti-acne composition: The present invention relates to a composition for treating acne comprising an anti-microbial peptide made from the amino acids phenylalanine, alanine, leucine and lysine with said peptide admixed with salicylic acid and/or salicylate salts in a cosmetic delivery vehicle containing a rehydrating polymer. The invention further relates to a method... Agent: K.f. Ross P.C.

20070207115 - Tea tree oil and benzoyl peroxide acne treatment: A system is disclosed consisting of tea tree oil used alone or in combination with conventional over-the-counter strength anti-acne agents. A system is created whereby Tea tree oil is used in combination with other anti-acne therapies, particularly benzoyl peroxide. Subsequent steps utilize conventional anti-acne treatments.... Agent: Greenberg & Lieberman, LLC

20070207117 - Composition for hands: A composition for use on the skin includes a carbomer, a starch, vitamins, moisturizers, an astringent, a Pluronic, dimethicone, and an aluminum compound. The composition may further include water, glycerin, emulsifiers, and surfactants. The composition provides therapeutic, conditioning, and other benefits to the skin, particularly when used on the hands,... Agent: Keely Schneiter, P.C.

20070207130 - Stem cell therapy to treat symptoms of avian flu and other diseases: The present disclosure relates to a method for the treatment of avian influenza using a stem cell preparation. Also described is a method for the manufacture of a stem cell preparation which can be used to treat the symptoms associated with avian influenza and a method for cryogenically preserving and/or... Agent: Lixian Jiang

20070207086 - Compounds that bind to p185 and methods of using the same: Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual... Agent: Darby & Darby P.C.

20070207088 - Anti-inflammatory analgesic adhesive patch: An anti-inflammatory analgesic adhesive patch which has an excellent anti-inflammatory analgesic effect and is reduced in unpleasant irritant feeling during wear. It is characterized by containing, as active ingredients, benzocaine and an ingredient having a counter-irritation effect, wherein the ingredient having a counter-irritation effect comprises one or more members selected... Agent: Ostrager Chong Flaherty & Broitman PC

20070207089 - Tamper resistant dosage form comprising an adsorbent and an adverse agent: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent... Agent: Duane Morris LLP Patent Department

20070207090 - Mucosal meningococcal vaccines: The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are... Agent: Novartis Vaccines And Diagnostics Inc.

20070207091 - Nebulizer formulation: A sterile nebulizer formulation contains formoterol and budesonide in about 2 ml or less of saline and is for treatment of COPD and asthma and other airways diseases and disorders.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070207092 - Oral hygiene products and method of using the same: The present invention is directed towards a composition for highly efficient and quick plaque and tartar removal and inhibition including pure ascorbic acid crystals and/or granulars (vitamin C) and an enamel repairing composition such as hydroxyapatite. The composition can contain from about 10% up to 90% of ascorbic acid without... Agent: Stephen E. Feldman

20070207094 - Hardenable thermally responsive compositions: Thermally responsive compositions that include a thermally responsive viscosity modifier, a polymerizable component, and water are provided. The compositions, which optionally may be hardened, are useful for application to a surface of a body.... Agent: 3m Innovative Properties Company

20070207093 - Hydrazone derivatives and uses thereof: e

20070207095 - Induction of a physiological dispersion response in bacterial cells in a biofilm: The present invention is directed to a compound which induces a physiological dispersion response in bacterial cells in a biofilm. The present invention is also directed to compositions containing this compound, methods of isolating the compound, and uses thereof.... Agent: Nixon Peabody LLP - Patent Group

20070207096 - Nail varnish having a gelled texture: Disclosed herein is a nail varnish comprising a cosmetically acceptable medium and at least one thixotropic thickener, wherein the composition has a viscosity at 25° C. of at least 0.6 Pa·s. Also disclosed herein is a cosmetic nail makeup process comprising lowering the viscosity of a nail varnish composition with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070207097 - Treating hair or nails with internal wool lipids: Animal or human hair or nails, eyelashes or eyebrows are treated with internal wool lipid extract.... Agent: Bacon & Thomas, PLLC

20070207098 - Antioxidant, whitening agent and external preparation for skin using the same: The present invention provides an antioxidant and a whitening agent having high safety, and a external preparation for skin using the same. The antioxidant and whitening agent comprise, as an effective component, one or more extracts from Basidiomycetes selected from the group consisting of Pleurotus abalonus, Pholiota squarrosa, Onnia orientalis,... Agent: Rankin, Hill, Porter & Clark, LLP

20070207102 - Compositions for topical applications comprising boron nitride: A topical composition with a sustained softness feel to the skin, comprising an effective amount of boron nitride suspended in a dermatologically acceptable carrier vehicle, wherein the composition suitably adheres to the skin, leaving a coating layer comprising boron nitride particles. The present invention also relates to a method of... Agent: Momentive Performance Materials Inc.-quartz C/o Dilworth & Barrese, LLP

20070207099 - Cosmetic preparations for the generation of a cosmetic covering with a metallic and multi-coloured shimmering appearance and artifical fingernail: The invention relates to a cosmetic composition for creating a cosmetic coating having a metallic and multicolored iridescent appearance, comprising a liquid phase and a PVD aluminum pigment, wherein said PVD aluminum pigment has diffractive structures containing from approximately 5,000 to approximately 20,000 structural elements per cm and a metallic... Agent: Ostrolenk Faber Gerb & Soffen

20070207105 - Anti-microbial compositions: Cosmetic and/or toiletry formulations having novel preservative blends including isothiazolinone and vicinal diols which are liquid at room temperature. The formulations provide antimicrobial properties including unexpectedly enhanced antifungal properties.... Agent: Flaster/greenberg P.C. 8 Penn Center

20070207109 - Personal care compositions containing cationic synthetic copolymer and a detersive surfactant: where k=1, each of v, v′, and v″ is independently an integer of from 1 to 6, w is zero or an integer of from 1 to 10, and X− is an anion. and; b) a detersive surfactant; and c) an aqueous carrier.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070207108 - Processes for producing cellooligosaccharide: A process of producing cellooligosaccharide, comprising enzymatically decomposing, in the presence of cellulase, a water-insoluble natural cellulosic material having an average degree of polymerization not greater than 700, an average particle size not greater than 100. A process of producing cellooligosaccharide, comprising enzymatically decomposing, in the presence of cellulase, a... Agent: Staas & Halsey LLP

20070207110 - Topical cosmetic compositions containing alpha arbutin: This invention is a topical tyrosinase inhibiting combination using alpha arbutin and bearberry extract, in synergism, for the purpose of skin lightening. The active admixture is a dermatological serum comprised of alpha arbutin, octyl stearate and polyolprepolymer-2, introduced onto the human skin in liposome form for ultra-deep penetration.... Agent: Oppenheimer Wolff & Donnelly LLP

20070207111 - Process for producing solubilized keratin: A process for producing a solubilized keratin of utility value easily with high yield while suppressing coloration and smelling occurring in the hydrolysis of keratin. There is provided a process for producing a solubilized keratin, characterized in that it comprises regulating the water content of keratin raw material to a... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070207113 - Personal care and cosmetic compositions comprising renewably-based, biodegradable 1,3-propanediol: Disclosed herein are personal care and cosmetic compositions comprising 1,3-propanediol, wherein the 1,3-propanediol in said personal care or cosmetic composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic... Agent: Mccarter & English, LLP Basil S. Krikelis

20070207106 - Low molecular weight ampholytic polymers for personal care applications: A cosmetically acceptable composition comprising from about 0.1 to about 10 weight percent, based on polymer solids, of a water-soluble ampholyte polymer comprising: from at least 1 to as much as 95 weight percent of the nonionic monomer acrylamide; from at least 5 to as much as 80 weight percent... Agent: Michael B. Martin Patent And Licensing Department

20070207114 - Hair growth agent composition: Disclosed herein is a composition for promoting hair growth. The composition comprises an Asiasari Radix extract as an active ingredient wherein the Asiasari Radix extract exhibits superior induction of the anagen phase of the hair growth cycle. The composition exhibits excellent hair loss prevention and hair growth promoting effects. In... Agent: Venable LLP

20070207118 - Surface modification of islet membranes by polymeric grafting methods: The present invention provides surface modification methods of pancreatic islet membranes by polymeric grafting. Particularly, the present invention provides the surface modification methods that hydrophilic polymer chain is grafted onto collagen membranes of the pancreatic islets by various polymeric grafting methods instead of encapsulation of the pancreatic islets. Since the... Agent: Alan J. Howarth

20070207116 - Antioxidant compositions for the eye: Ophthalmic compositions comprising at least one antioxidant agent chosen from a carotenoid, glutathione, reduced glutathione, glutathione enhancers, a lipoic acid, a flavonoid, an oleanoic acid, ascorbyl palmitate, aloe vera extract, an omega-6 fatty acid, melatonin, and vitamin E acetate.... Agent: Baker Botts, LLP

20070207119 - Histone deacetylase inhibitor enhancement of trail-induced apoptosis: Due to the poor long-term clinical outcome in the adult patients with several forms of acute leukemia novel treatment strategies are needed to overcome resistance and sensitize the leukemia blasts to the extrinsic and intrinsic pathway of apoptosis. Treatment with LAQ824 and Apo-2L/TRAIL alone has been recognized to induce apoptosis... Agent: Smith Hopen, Pa

20070207120 - Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6: This invention relates to up-regulation of the acetyltransferase MCM3AP by the administration of the cytokines TNFalpha and IL-6 and, optionally a deacetylase inhibitor. This up-regulation is shown herein to be selectively lethal to cancer cells and has applications in the treatment of cancer.... Agent: Klarquist Sparkman, LLP

20070207122 - Compositons and methods of use of ritonavir for treating hcv: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metaboilized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.... Agent: Robert Deberardine Abbott Laboratories

20070207121 - Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms,... Agent: Jones Day

20070207123 - Amelioration of effects of cigarette smoke: Aerosolized Substance P can be used to mitigate the effects of main-stream or side-stream cigarette smoke. Functional, structural, genetic, organ limited, and systemic effects of the smoke are mitigated by the Substance P treatment.... Agent: Banner & Witcoff, Ltd.

20070207124 - Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain: The invention provides a vector, preferably a herpes simplex virus (HSV) vector, comprising a polynucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein. The invention also provides a stock of such vectors and a pharmaceutical composition comprising such vectors. The invention further provides a method of treating pain, such as... Agent: Leydig Voit & Mayer, Ltd

20070207133 - Emulsifier composition for shortening: A method of producing a water-in-oil product is described. The method comprises the step of: admixing a hydrophobic component with a water-in-oil emulsion to form said water-in-oil product, wherein said hydrophobic component comprises a probiotic in a hydrophobic medium.... Agent: Steptoe & Johnson LLP

20070207134 - Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm: The invention provides agents for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm and for improving a circadian rhythm, which may be taken daily and continuously, have excellent safety, and may effectively prevent or ameliorate disorders of an endogenous melatonin secretion rhythm or of a circadian rhythm... Agent: Sughrue Mion, PLLC

20070207132 - Synbiotic composition for infants: There is provided a preparation comprising Bifidobacterium breve and a mixture of non-digestible carbohydrates for non- or partially breast-fed infants as well as the use thereof for the treatment or prevention of immune disorder in non- or partially breast-fed infants. Also provided herein are sequence primers and probe for the... Agent: The Webb Law Firm, P.C.

20070207129 - Compositions and methods for inducing chimerism in a subject: Prevention of autoimmune disease and induction of transplantation tolerance in a recipient can be achieved by induction of mixed chimerism via bone marrow transplantation (BMT), but this procedure requires total body irradiation (TBI)-conditioning of the recipient. The toxicity of radiation and potential for graft versus host disease (GVHD) prevents its... Agent: Perkins Coie LLP

20070207131 - Compositions for regenerating tissue that has deteriorated, and methods for using such compositions: A composition for promoting regeneration of tissue which has degenerated in a subject as a result of a disease or disorder and a method of using the composition is provided. The composition comprises a biodegradable acellular matrix, and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived... Agent: Fish & Richardson P.C.

20070207128 - Method for treating autoimmune diseases and compositions therefor: A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fcγ receptor-specific complex or a complex which results in the co-crosslinking of Fcγ-chains for treating the leukocytes and/or... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070207127 - Method of inducing the differentiation of amnion-derived cells and utilization of the same: By a method of inducing differentiation of cells having: a step of co-culturing amniotic epithelial cells and amniotic interstitial cells so as to induce their differentiation into predetermined tissue cells, it is possible to efficiently induce differentiation of the amniotic epithelial cells and the amniotic interstitial cells. It is preferable... Agent: Harness, Dickey & Pierce, P.L.C

20070207126 - Therapeutic microencapsulation of embedding parathyroid live cells with theracyte and a manufacturing method thereof: A therapeutic microencapsulation for embedding parathyroid live cells with TheraCyte® and a manufacturing method are disclosed, where in the agent is made by embedding at least 4×105 parathyroid live cells with TheraCyte®. The achieved agent can be planted into mammal objects for treating osteoporosis in long-term. The manufacturing method is... Agent: Nikolai & Mersereau, P.A.

20070207125 - Vascularized human skin equivalent: Clinical performance of currently available human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equivalents in vivo. Living skin equivalents were constructed by sequentially seeding the apical and basal surfaces... Agent: Kathryn R. Doyle, Ph.d. Drinker Biddle, LLP

20070207135 - Drip tray tablet: A tablet for use in a drip tray including an excipient selected so that the tablet will not fully dissolve in water at ambient temperature for a period of at least one month, more preferably up to 12 months, a biocide, at least one enzyme, preferably a proteolytic or hydrolase... Agent: Edwards Angell Palmer & Dodge LLP

20070207136 - Food and vitamin preparations containing the natural isomer of reduced folates: A composition for human or animal consumption for supplying folate which includes a natural isomer of reduced folate, such as (6S)-tetrahydrofolic acid. 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and their polyglutamyl derivatives is disclosed. Such compositions include multivitamin preparations (with or without minerals and... Agent: Peter Rogalskyj, Esq. Rogalskyj & Weyand, LLP

20070207137 - Inhibition of jun kinase: A method of treating a metabolic disorder associated with insulin resistance by administering to a mammal an inhibitor of a NH2-terminal Jun Kinase (JNK), e.g., a compound or peptide which inhibits JNK1 expression or enzymatic activity.... Agent: Edwards Angell Palmer & Dodge LLP

20070207138 - S/o type pharmaceutical preparation and method for producing the same: The present invention provides a pharmaceutical preparation that significantly reduces leakage of a low-molecule medicine in a strong acidic environment, while allowing release of the low-molecule medicine in the enteric canal or the like which is in a weak acidic to neutral environment. The S/O type pharmaceutical preparation of the... Agent: Fitch, Even, Tabin & Flannery

20070207139 - Enhancing the effect of therapeutic proteins on the central nervous system: The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20070207140 - Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same: KCC2, KCC3, and KCC4 potassium-chloride cotransporter proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to KCC2, KCC3, and KCC4 homologs, and methods of producing the same, are also... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070207141 - Methods of treating inflammatory and autoimmune diseases with natalizumab: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070207143 - Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26: Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.... Agent: Fulbright & Jaworski L.L.P.

20070207142 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070207145 - Mouse/human chimeric anti-phencyclidine antibody and uses thereof: The present invention provides a chimeric mouse/human antibody (ch-mAb6B5) for treatment of abuse and toxicity of the arylcyclohexylamines class of drugs (i.e., phencyclidine- or PCP-like drugs). This antibody comprises light and heavy chain PCP binding regions of mouse mAb6B5, coupled to the light and heavy chain constant regions of a... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070207144 - Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy: The present invention provides compositions and method for the treatment of spinal muscular atrophy comprising administering a therapeutically effective amount of a therapeutically amount of at least one proteasome inhibitor to a subject in need of treatment of spinal muscular atrophy.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070207146 - Therapeutic using a bispecific antibody: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may... Agent: Faegre & Benson LLP Patent Docketing

20070207147 - Secreted and transmembrane polypeptides and nucleic acids encoding the same: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides... Agent: Genentech, Inc.

20070207148 - Genes associated with obesity and methods for using the same: The instant invention is concerned with genes associated with obesity. Additionally, the invention provides methods of using the differential expression of these genes associated with obesity to diagnose and treat obesity, as well as to screen for compounds useful for treating obesity.... Agent: Merchant & Gould PC

20070207151 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Nixon & Vanderhye, PC

20070207149 - Cancer treatment using viruses and camptothecins: Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma... Agent: Lewis J. Kreisler

20070207150 - Modified annexin proteins and methods for their use in organ transplantation and in prevention of thrombosis and reperfusion injury: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex.... Agent: Swanson & Bratschun, L.L.C.

20070207152 - Human bnp immunospecific antibodies: The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies... Agent: Robert Deberardine Abbott Laboratories

20070207153 - Therapeutic agents for inner ear disorders containing an il-6 antagonist as an active ingredient: A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20070207155 - Glycoprotein vi antibodies and methods of use thereof: The present invention describes antibodies generated against platelet membrane glycoprotein VI (GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research, diagnostic and immunotherapeutic agents, in particular, as diagnostic and therapeutic agents for the detection and treatment of thrombosis and other vascular diseases.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070207154 - Method of modulating vascularization: A method of modulating vascularization in a tissue of a mammal comprises controlling a PAR signaling pathway (e.g., the PAR-1 or PAR-2 signaling pathway) in a mammalian tissue, for example, by controlling phosphorylation of tissue factor cytoplasmic domain (i.e., phosphorylation of Ser258 of the cytoplasmic tail of TF). In a... Agent: Olson & Hierl, Ltd.

20070207157 - Adjuvant theraphy of g250-expressing tumors: The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasising disease.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070207158 - Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof: A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes... Agent: Dunlap, Codding & Rogers P.C.

20070207156 - Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules: The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenström's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.... Agent: Howrey LLP

20070207159 - Compositions and methods for enhancing antigen-specific immune response: Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a composition comprising a purified OX-40 receptor binding agent and a pharmaceutically acceptable carrier, wherein said composition is administered... Agent: Klarquist Sparkman, LLP

20070207160 - Apoptosis inhibitors: This invention relates to compositions for inhibiting apoptosis, containing one to all components of: (a) an APO-1-inhibiting compound; (b) a compound inhibiting and catching, respectively, the APO-1 ligand; and (c) a compound inhibiting the intracellular APO-1 signalling pathway, the component(s) being not considered foreign in an individual, as well as... Agent: Nixon Peabody, LLP

20070207161 - Immunomodulating compositions and uses therefor: The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses. The compositions of the present invention are particularly useful in the treatment and/or prophylaxis of a range of... Agent: Knobbe Martens Olson & Bear LLP

20070207162 - Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system: Compositions and methods for suppressing the immune system of a mammal using ubiquitin and derivatives and analogs thereof... Agent: Venable LLP

20070207164 - Methods of using flt3-ligand in the treatment of cancer: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and... Agent: Sughrue Mion, PLLC

20070207163 - Recombinant soluble fc receptors: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very... Agent: Fulbright & Jaworski, LLP

20070207165 - Piscirickettsia salmonis antigens and use thereof: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention further provides... Agent: Lucas & Mercanti, LLP

20070207167 - Immunologically enhanced recombinant vaccines: The present invention is directed to recombinant vaccines, based on a phage vector system, which enhance immunological response and allow rapid construction and deployment of vaccines.... Agent: M. Elisa Lane Hygea Biopharma, Inc.

20070207166 - Method of using adenoviral vectors to induce an immune response: The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune... Agent: Leydig, Voit & Mayer, Ltd.

20070207168 - Use of vaccines for the treatment/prevention of the transmission of pathogens: The present invention relates to a method for prevention of the transmission of a pathogen of an animal of a first species to an animal of a second species characterized in that antigen of a pathogen of an animal of a first species is used for the immunization of an... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070207169 - Early childhood infection with human herpes virus type 6 (hhv-6) as a protection against the development of ige sensitization, atopic disease and allergy in young children: The present invention discloses a use of human herpes virus 6 (HHV-6) or derivatives thereof, for the manufacture of a pharmaceutical composition intended to be administered during early childhood, for the prevention of IgE sensitization and allergy development in young children. Examples of viral compositions include, but are not limited... Agent: Gauthier & Connors, LLP

20070207170 - Engineered listeria and methods of use thereof: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.... Agent: Morrison & Foerster LLP

20070207171 - Engineered listeria and methods of use thereof: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.... Agent: Morrison & Foerster LLP

20070207172 - Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus: The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be... Agent: Morrison & Foerster LLP

20070207173 - Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof: The present invention provides vitamin E succinate (VES)-stabilized compositions, methods for the preparation thereof and methods useful for the in vivo delivery of substantially water insoluble and optionally chemically unstable pharmacologically active agents (such as docetaxel).... Agent: Seed Intellectual Property Law Group PLLC

20070207176 - Powder treated with a power treating agent comprising an organopolysiloxane and cosmetic comprising the powder: Powder treated with a powder treating agent comprising organohydrogenpolysiloxane, characterized in that the organohydrogenpolysiloxane has a weight average molecular weight of from 300 to 100,000, at least one SiH bond per molecule, and at least one selected from (R23SiO1/2) unit and (SiO2) unit, wherein R1 is selected from the group... Agent: Birch Stewart Kolasch & Birch

20070207175 - Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof: w

20070207174 - Encapsulated fragrance materials and methods for making same: The present invention is directed to novel capsules containing active materials and methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products.... Agent: International Flavors & Fragrances Inc.

20070207177 - Methods of preparing pesticide formulations and their methods of use: The present invention provides formulations which greatly improve the physical and chemical stability of pesticides such as insect growth regulators, in liquid feeds, and liquid feed supplements. The present invention prevents or reduces stratification in liquid feeds and liquid feed supplements.... Agent: Townsend And Townsend And Crew, LLP

20070207178 - Biocide composition comprising pyrithione and pyrrole derivatives: The present invention is directed to a biocidal composition comprising a blend of one or more pyrithione compounds, and one or more pyrrole compounds of Formula I wherein said biocidal composition is copper free or low copper content.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070207181 - Coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer: Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.... Agent: Squire, Sanders & Dempsey LLP

20070207185 - Compositions and methods for treating bone: The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070207184 - Implantable medical device coated with a bioactive agent: The present invention provides an implantable medical device comprising a bioactive agent and poly(alkyl cyanoacrylate) polymer. In one embodiment of the invention, the bioactive agent is a water-soluble material, such as an antisense agent.... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20070207179 - Medical device: A medical device, such as a guide wire, an embolization device, or a guide shaft for a micro catheter, comprises a solid and/or non-expandable core member made from e.g. metal, such as tantalum, and an outer surface layer, which is formed by electrospun nanofibers. The outer surface layer may incorporate... Agent: Roetzel And Andress

20070207182 - Medical devices having electrically aligned elongated particles: Medical devices configured for implantation or insertion into a subject, which contain one or more particle-containing region that comprises electrically aligned, elongated particles within a matrix. Also described are methods for forming the same.... Agent: Mayer & Williams PC

20070207180 - Synthetic polypeptide-containing bioapplicable material and film-forming material: The present invention provides a bioapplicable material (or composition) or film-forming material (or composition), which is free from a risk of an infection by a pathogenic organism or a transmission of a causative factor, has a high safety. The material (or composition) comprises a collagen-like synthetic polypeptide having at least... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070207183 - Zein coated medical device: The invention relates to medical devices coated with zein. The medical device may include further a therapeutic agent in contact with zein. Zein allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The invention further... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20070207186 - Tear and abrasion resistant expanded material and reinforcement: The present invention is a more durable expanded material that enables thinner wall thicknesses and a more flexible reinforcement suitable for stenting. The present invention is especially useful in the construction of grafts, stents, and stent-grafts which are used, for example, in repairing or replacing blood vessels that are narrowed... Agent: John J. Scanlon

20070207187 - Functional composition or food comprising whey protein, antibody derived from milk or antibody: There is provided a functional composition or food comprising whey protein, an antibody derived from milk or the other antibody; and a whey protein food comprising whey protein and glucide, cocoa powder, powdery an unsolidifiable and insoluble substance, green tea, aloe, turmeric, pumpkin, red grape juice, tomato, cranberry, raspberry, blueberry... Agent: Flynn Thiel Boutell & Tanis, P.C.

20070207188 - Cocoa products and methods of treating cardiovascular conditions with sugar-free cocoa: The invention provides, in one aspect, a method of administering a product comprising a cacao solids-containing, cocoa powder or extract containing cocoa polyphenols to improve endothelial function. The sugar-free compositions and methods of using them exhibit synergistically improved cardiovascular benefits compared to other compositions. Preferred sugar-free chocolate products and cocoa... Agent: Wiley Rein LLP

20070207189 - Antimicrobial medical devices: Antimicrobial medical devices are prepared with a complexed antimicrobial agent which enhances the adherence of the antimicrobial agent to the medical device.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070207190 - Process for manufacturing hydrophobic polymers: Method for producing hydrophobic polymers, wherein a hydrophobic polymer is selected; a set of organisms is selected from among cells and/or cell products; aggregates are formed by working said cells and/or cell products in said polymers resulting in the formation of a so-called polymer-bio aggregate, wherein there is performed a... Agent: Birch Stewart Kolasch & Birch

20070207192 - Adhesive bioerodible transmucosal drug delivery system: The present invention is directed to a mucoadhesive delivery system for the local or systemic administration of a pharmaceutical agent. The delivery system of the invention effectively and facilely enables transport of the pharmaceutical agent through mucosal membranes and into the vasculattire of the mucosa. The delivery system includes an... Agent: Lahive & Cockfield, LLP

20070207193 - Novel application of topical anesthetics for modulation of neurogenic tremor: A method of ameliorating neurogenic tremor in mammals, which comprises topically administering to a mammal, which has been diagnosed with a neurogenic tremor, an effective amount of a topical anesthetic.... Agent: Birch Stewart Kolasch & Birch

20070207191 - Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases: Compositions and methods are provided that comprise improved means to achieve and maintain a targeted level of copper status in persons in order to treat and prevent copper associated diseases.... Agent: Hayes Soloway P.C.

20070207197 - Composition and method for reducing symptoms of breast engorgement: A composition and method used to reduce the symptoms associated with breast engorgement, galactorrhea, and other associated disorders. More specifically, this invention is related to a cabbage extract combined with a base cream having liposomes that are applied to each breast of a patient suffering from a symptom of breast... Agent: T. Ling Chwang

20070207194 - Gene or drug delivery system: The present invention includes compositions and methods for delivering one or more active agents in vivo by contacting a target organ or tissue with a microbubble encapsulated active agent comprising a neutrally charged lipid microbubble loaded with cationic liposomes comprising one or more active agents and selectively releasing the active... Agent: Chalker Flores, LLP

20070207195 - Genetic screening for polymorphisms in human genes that increase or decrease sensitivity to toxic agents: Methods are disclosed for genetically counseling a person based on one or more polymorphisms in his or her genes that sensitize him or her to toxic agents. Methods are also disclosed for genetically screening a group of individuals and/or a human population, based on, for example, ethnicity, race, religion or... Agent: Maurice M Klee

20070207196 - Tocopherol-modified therapeutic drug compound formulations: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070207199 - Appetite suppression device: An appetite suppression device includes an ingestible, expandable membrane in surrounding an expandable reactant material. The membrane is contained in a capsule. A reactant enabling mechanism is integrated with the expandable membrane to enable the reactant after ingestion of the membrane by a subject. enabling mechanism may comprise a pore... Agent: Vierra Magen Marcus & Deniro LLP

20070207200 - Dosage forms for administering combinations of drugs: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption... Agent: Law Office Of Michael A. Sanzo, LLC

20070207198 - Use of n-acety1-d-glucosamine in the manufacture of medicaments for anti-tumors and anti-metastasis: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicament for treating tumors and metastatic diseases. N-acetyl-D-glucosamine is able to regulate cellular membrane, constitute a stable structural component of cellular membrane, participate metabolism process of tumor cells, and stop energy supply to cause the death... Agent: Fulbright & Jaworski, LLP

20070207201 - Liquid and semi-solid pharmaceutical formulations and processes: The present invention is directed to liquid or semi-solid pharmaceutical formulations of pharmacologically active agents of Formula I that are estrogen receptor modulators, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20070207202 - Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to pharmaceutical formulations of a monohydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20070207203 - Oral controlled release formulation for sedative and hypotnic agents: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.... Agent: Hedman & Costigan P.C.

20070207204 - Dosage form for time-varying patterns of drug delivery: The present invention provides a multi-release oral drug delivery system that initiates drug release following an initial drug-free release interval, after administration to a subject, and a second drug-free release period before release of another dose of drug. The system has (1) inner compartments enclosed within a semipermeable membrane, and... Agent: Dewipat Incorporated

20070207208 - Compositions and methods using a cardiac glycoside: A method of treating patients suffering from renal failure and concomitant cardiovascular disease with a low dose of the cardiac glycoside known as digoxin, and novel dosage forms to accomplish the method and to perform other uses.... Agent: Accu-break Technologies, Inc.

20070207207 - Bioadhesive drug formulations for oral transmucosal delivery: Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.... Agent: Dla Piper US LLP

20070207206 - Chewable pain formula: One embodiment of a chewable pain relief composition includes acetaminophen, present in a therapeutically-effective amount, ibuprofen, present in a therapeutically-effective amount, and a chewable binding agent, present in an amount effective to facilitate breakdown of the composition during chewing thereof.... Agent: Ingrid Mctaggart

20070207205 - Rapidly disintegrating taste-masked tablet: The present invention concerns a rapidly disintegrating taste-masked tablet having both hardness and non-friability properties comprising at least one active principle selected from the group of mineral salts, vitamins and mixtures thereof, the active principle being coated by a sweetening agent wherein the weight ratio of the active principle to... Agent: Frost Brown Todd, LLC

20070207209 - Trophic factor combinations for nervous system treatment: The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor... Agent: Whyte Hirschboeck Dudek S C

20070207211 - Emulsion-based microparticles and methods for the production thereof: The apparatus, methods and compositions of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. The apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable... Agent: The Mccallum Law Firm, P. C.

20070207210 - Protein microspheres retaining pharmacokinetic and pharmacodynamic properties: The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in... Agent: Baxter Healthcare Corporation

20070207213 - Injectable microspheres from unsaturated functionalized polyhydric alcohol esters: Injectable drug laden microspheres are obtained from unsaturated functionalized polyhydric alcohol ester of polyester by a method comprising dissolving the unsaturated functionalized ester in a hydrophobic organic solvent, dissolving drug and/or biologically active agent in water, admixing the two solutions to form water-in-oil emulsion, forming an aqueous solution of stabilizer,... Agent: Bacon & Thomas, PLLC

20070207212 - Polypeptide films and methods: Disclosed herein is a method of making a film, the method comprising depositing a first layer polyelectrolyte on a surface of a substrate to form a first layer; and depositing a second layer polyelectrolyte on the first layer polyelectrolyte to form a second layer. The first layer polyelectrolyte, the second... Agent: Cantor Colburn, LLP

20070207214 - Oral pharmaceutical compositions with controlled release and prolonged absorption: The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without... Agent: Patton Boggs LLP

20070207215 - Medicament on the basis of honey, preparation and use thereof: Honey is treated thermally At 100-160° and the obtained solution is settled. Then the solution is mixed with adsorbent and again settled, further it is filtered. The obtained filtrate represents a soluble medicinal means pH of which is 3-4. To receive a dry powder the soluble filtrate is mixed with... Agent: Merchant & Gould PC

20070207216 - Flavored colonic cleansing system: A kit for colonic cleansing includes a phosphate salt laxative, a flavorant, and an oral rehydration mixture. The flavorant includes aspartame and a citrate, and the oral rehydration mixture includes sodium and a glucose containing saccharide. The kit may be used for a colonic cleansing procedure by combining the phosphate... Agent: Evan Law Group LLC

20070207218 - Combinations of vanadium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070207217 - Method for treating a mammal by administration of a compound having the ability to release co: The present invention relates to molybdenum carbonyl complexes useful for inhibiting tumor necrosis factor (TNF) production and for treating inflammatory diseases.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070207220 - Method for improving sleep behaviors: The invention relates to a method for improving the sleep behaviors of a human comprising the administration of a sensory regimen which comprises: a. the administration of a first sensory experience comprising topically applying to the skin or hair of the human a cleansing product containing an effective amount of... Agent: Philip S. Johnson Johnson & Johnson

20070207219 - Method for producing mallotus philippinensis dye composition and the composition: An object of the present invention is to provide a Mallotus philippinensis extract containing readily water soluble rottlerin. A further object of the present invention is to improve convenience at production steps in a method for producing such an extract, by avoiding the staining of filters and/or pipes during extraction... Agent: Drinker Biddle & Reath (dc)

20070207221 - Pesticidal compositions containing rosemary oil and wintergreen oil: Pesticidal compositions containing rosemary oil and/or wintergreen oil and methods for using same are disclosed.... Agent: Nixon & Vanderhye, PC

20070207222 - Composition and method for topical treatment of tar-responsive dermatological disorders: The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatological disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070207223 - Means for improving cardiovascular health: The present invention is in the fields of lipid metabolism and dietary supplementation and provides methods and compositions to improve heart health of a mammal by orally administering stearidonic acid and related compounds to the mammal. The improved heart health is evidenced by the enrichment of cardiac tissue with eicosapentaenoic... Agent: Monsanto Company

20070207224 - Health care product containing isoflavone aglycones and method of producing the same: This invention relates to a novel soy isoflavone product with high purities and strong biological activities and the method of producing the same from natural soybeans, soybean materials (i.e. tofu dregs, soy molasses) and other plant sources. The method includes three steps consisting of extraction with an organic solvent, hydrolysis... Agent: EagleIPLimited

20070207225 - Genistein modulated reduction of cardiovascular risk factors: The disclosed methods and compositions for reducing cardiovascular risk factors in mammals generally includes using genistein to modulate various inflammatory and cardiovascular risk markers including: homocysteine, C-reactive protein, fibrinogen, sex hormone-binding globulin, fasting glucose, insulin, insulin resistance, and osteoprotegerin.... Agent: Noblitt & Gilmore, LLC.

20070207226 - Composition for enhancing muscle mass development in animals: Compositions containing nicotine and/or nicotinic acetylcholine receptor agonists are provided for administration in therapeutically effective amounts to enhance muscle development in animals, the nicotine and/or nicotinic acetylcholine receptor agonists being particularly derived from natural sources that produce beneficially high amounts nicotine and/or nicotinic acetylcholine receptor agonists which is also well-tolerated... Agent: Holme Roberts & Owen, LLP

20070207227 - Appetite suppressant compositions: An inherently nourishing edible appetite suppressant product comprising a steroidal glycoside, preferably obtainable from plants of the Asclepiadaceae family, the product being in the unit serving, having a weight of from 20 to 600 grams, and having the energy density of from 1.6 to 23 kilojoules per gram of product.... Agent: Unilever Intellectual Property Group

20070207228 - Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenic alopecia: The present invention relates to a composition for regulating the trophism of hair follicles and the cutaneous production of sebum and its use in androgenetic alopecia, comprising the synergic association of an extract from Boehmeria Nippononivea with a compound active at the keratin epithelial structure level, selected from specific sulfur-donor... Agent: James V Costigan Hedman & Costigan

20070207229 - Inhibitor of blood glucose level elevation and inhibitor of age generation comprising acerola leaf extract and food product comprising either thereof: This invention is directed to providing an inhibitor of blood glucose level elevation and an inhibitor of AGE generation made from natural ingredients and a food product comprising either thereof. Such inhibitor of blood glucose level elevation or inhibitor of AGE generation comprises, as an active ingredient, an acerola leaf... Agent: Sughrue Mion, PLLC

20070207230 - Extract of nelumbinis semen for the treatment of depression, medicinal composite and health foods including the extract of nelumbinis semen: Disclosed are an extract of Nelumbinis Semen (Nelumbo nucifera) having an antidepressive effect, and a pharmaceutical composition and a health food for treating depression, comprising the extract, The Nelumbinis Semen extract is prepared by extracting Nelumbinis Semen with hot water. Animal behavioral and biochemical studies revealed that the Nelumbinis Semen... Agent: Sheridan Ross PC

20070207231 - Composition and use of phyto-percolate for treatment of disease: This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease states.... Agent: John C. Serio Brown Rusnick Berlack Israels, LLP